Celiac disease can significantly influence the immune system. Find out what you need to know to stay healthy and informed.

Abstract

This educational post explores one of the most misunderstood areas in modern gastroenterology and functional medicine: the critical distinction between celiac disease and non-celiac gluten sensitivity (NCGS). Conventional medicine has often conflated these two conditions, but they are mechanistically distinct, clinically different, and require separate approaches to diagnosis and management. Drawing on the latest evidence-based research and years of clinical observation, this post walks you through the immunological underpinnings of each condition, explains why the intestinal barrier is central to the conversation, and shows how threshold dynamics help explain why so many patients don’t develop symptoms until well into adulthood.

Beyond the science, this post explains why proper diagnostic testing matters, why a gluten-free diet without a confirmed diagnosis can actually sabotage your test results, and why cross-reactivity between gluten and dairy is not a myth but a well-documented biological reality. We will also look at the cascade of downstream consequences that follows unchecked gluten exposure in a susceptible individual, including osteoporosis, neurological damage, cardiovascular injury, nutrient malabsorption, adrenal exhaustion, and skin manifestations.

Finally, this post introduces the integrative model practiced at Injury Medical Clinic PA in El Paso, Texas, where Dr. Alex Jimenez, DC, APRN, FNP-BC, and Dr. Maria Guadalupe Cardenas, MD, Board-Certified Internist with over 40 years of clinical experience, collaborate as a multidisciplinary team to deliver comprehensive, patient-centered care that bridges chiropractic medicine, internal medicine, functional medicine, personal injury rehabilitation, and evidence-based nutrition. If you or someone you love has been told they “might be gluten sensitive” without a clear explanation of what that actually means, this post was written for you.

Introduction: Why the Gluten Conversation Is More Complex Than You Think

If you have ever walked into a doctor’s office and mentioned that gluten seems to be making you feel unwell, you have probably encountered one of two responses. Either you were handed a celiac disease panel and told to wait for results, or you were told that unless the test is positive, there is nothing medically wrong and you should not worry about gluten at all. Both responses, while well-intentioned, dramatically oversimplify a biological story that is far more layered, nuanced, and consequential than most people realize.

I have been practicing integrative and functional medicine for many years, and the overlap between what the research is now telling us about gluten-related disorders and what I see clinically every week in El Paso, Texas, is striking. Patients come in with fatigue that no one can explain, skin rashes that dermatologists have been treating symptomatically for years, joint pain that gets attributed to age, and neurological symptoms that have been written off as anxiety or stress. When we dig into immunology, gut biology, and what has been going into the body over decades, gluten and its interaction with the immune system often sit at the center of the picture.

What makes this topic so important is precisely that celiac disease and non-celiac gluten sensitivity are not the same condition. They share a common dietary trigger and can share some overlapping symptoms, but the underlying mechanisms, diagnostic approaches, long-term consequences, and management strategies are entirely different. Treating them as the same thing does patients a significant disservice, and unfortunately, that still happens in many clinical settings.

This educational post is my attempt to give you the complete picture. I want to walk you through the immunology in a clear, accessible way, explain the anatomy and physiology of the gut in enough detail that the cascade of events makes intuitive sense, and connect that science to real clinical decision-making and treatment options. I also want to introduce you to the team at Injury Medical Clinic PA, including my collaborating physician Dr. Maria Guadalupe Cardenas, MD, whose decades of internal medicine expertise are essential to the comprehensive, integrative approach we take with every patient.

Whether you have already been diagnosed with one of these conditions, are still searching for answers, or are a clinician looking to deepen your understanding, I believe this post will be genuinely useful.

Meet the Clinical Team: Dr. Alex Jimenez and Dr. Maria Guadalupe Cardenas

An Integrative, Multidisciplinary Model of Care

At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas, we have built a clinical environment that intentionally breaks down the silos that so often separate different areas of medicine. The premise behind everything we do is straightforward: patients are whole human beings, and the conditions they present with rarely exist in isolation. A patient with chronic low back pain almost certainly also has inflammation driving that pain. A patient with peripheral neuropathy may have underlying metabolic dysfunction. A patient with what looks like an autoimmune skin condition may have a gut barrier problem that is feeding the immune system’s fire. Treating any of these presentations well requires a team that can see across disciplines.

I am Dr. Alex Jimenez, and I hold the following credentials: DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. My clinical background spans chiropractic medicine, advanced practice nursing as a Family Nurse Practitioner Board-Certified through the ANCC, functional medicine through the Institute for Functional Medicine, and clinical training in neuromusculoskeletal care, sports medicine, and rehabilitation. I have spent most of my career integrating these disciplines into a single coherent framework for each patient, and the clinical observations I have made over the years in practice, which are documented at SciaticaClinicc and through my professional work available on LinkedIn, inform everything I present here.

Our Medical Director and Collaborative Physician is Dr. Maria Guadalupe Cardenas, MD, who holds NPI #1164426749 and Texas MD License #J2933. Dr. Cardenas is board-certified in Internal Medicine and brings more than 40 years of clinical experience as an internist to our team. That depth of experience can’t be replicated quickly. Over four decades of practice, Dr. Cardenas has seen the full spectrum of how systemic illness presents, progresses, and responds to treatment. Her expertise in internal medicine gives our team the medical oversight and diagnostic depth that is essential when we are working with patients who have complex, multi-system presentations, which is precisely the kind of patient who often ends up in our clinic after years of searching for answers.

How the Collaboration Works

Our clinic’s structure reflects what the research literature increasingly recognizes as best practice for managing complex chronic conditions: a multidisciplinary integrative model in which different areas of clinical expertise coordinate rather than operate in isolation. Under this model, Dr. Cardenas provides the medical direction and internal medicine oversight that grounds our clinical decision-making in conventional evidence-based medicine. She reviews patient histories, oversees laboratory workups, co-manages patients with complex systemic presentations, and provides the physician-level medical oversight required for the full scope of services we offer.

As a Doctor of Chiropractic and Advanced Practice Registered Nurse, I bridge structural and neurological care, functional and nutritional medicine, and direct patient education. I conduct detailed functional medicine assessments, interpret advanced laboratory panels, design and implement nutritional and supplement protocols, and provide chiropractic and neuromusculoskeletal care as appropriate to each patient’s presentation.

Together, our team also incorporates:

• Functional medicine evaluation and protocol design for chronic and complex conditions
• Personal injury care including post-accident rehabilitation, whiplash, and soft tissue injury management
• Rehabilitation services including corrective exercise, physical therapy modalities, and neuromuscular re-education
• Advanced laboratory analysis including comprehensive gut health panels, food sensitivity testing, inflammatory markers, hormone panels, and metabolic assessments
• Nutritional medicine including therapeutic elimination diets, gut restoration protocols, and anti-inflammatory dietary strategies
• Chiropractic care targeting spinal alignment, nerve function, and musculoskeletal health as they relate to systemic wellbeing.

This integrated model is particularly valuable in the context of gluten-related disorders because, as you will see throughout this post, these conditions are not simply digestive issues. They are systemic immune events with consequences that extend into the musculoskeletal system, the nervous system, the skin, the cardiovascular system, and the endocrine system. Addressing them comprehensively requires exactly the kind of multidisciplinary team we have assembled at Injury Medical Clinic PA.

Celiac Disease vs. Non-Celiac Gluten Sensitivity: Two Completely Different Conditions

The Fundamental Distinction That Changes Everything

One of the most important clinical points I want to make in this post seems simple on the surface but has profound implications for how these conditions are diagnosed, managed, and explained to patients: celiac disease. Non-celiac gluten sensitivity is a different condition. They are not different degrees of severity along the same spectrum. They are not one condition with a “mild” and a “severe” form. They are mechanistically distinct disorders that happen to share a common dietary trigger.

This distinction matters enormously, and yet in many clinical settings, patients with either condition receive nearly identical advice: avoid gluten. While that dietary recommendation is correct for both conditions, giving the same advice without explaining the different mechanisms, long-term risks, and diagnostic approaches does a significant disservice to the patient. A person with celiac disease who does not understand that their immune system is permanently sensitized, that even small exposures can trigger ongoing tissue destruction, and that dairy cross-reactivity is a documented biological reality may go “mostly gluten-free” and continue to suffer. A person with NCGS who is told they have “the same thing as celiac” may unnecessarily restrict their diet for life and live with unwarranted health anxiety about exposures that would not cause the same level of structural damage.

Let me walk you through what makes each condition unique, starting with the immune mechanisms that drive each one.

Celiac Disease: The Key Characteristics

• Celiac disease is an adaptive immune-mediated condition, meaning it involves a highly specific, antigen-driven immune response that is learned, remembered, and repeatable.
• It involves the production of specific IgG and IgA antibodies directed against the body’s own biological tissue, making it a true autoimmune disease.e
• The primary targets of the immune attack include intestinal villi, the endothelium, and the skin
• The condition is permanent: once the adaptive immune system mounts this response and creates immunological memory, the sensitization does not go away.
• Tissue destruction is cumulative: every exposure to gluten triggers another round of immune activation and tissue damage.
• The long-term consequences of unmanaged celiac disease include osteoporosis, neurological damage, cardiovascular injury, anemia, infertility, and elevated cancer risk, particularly enteropathy-associated T-cell lymphoma.a
• Celiac disease requires strict, lifelong gluten elimination, with no exceptions.

Non-Celiac Gluten Sensitivity: The Key Characteristics

• NCGS is an innate immune response, meaning it involves the non-specific, front-line arm of the immune system rather than the adaptive, antibody-producing arm
• It is driven primarily by the structural properties of wheat proteins and other components of wheat,t including amylase trypsin inhibitors (ATIs) and fructans, rather than by an antibody-mediated autoimmune process
• Intestinal villi are not destroyed in NCGS the way they are in celiac disease
• The condition can range from mildly uncomfortable to significantly disruptive in terms of quality of life, but it does not carry the same risk of permanent tissue destruction
• NCGS may be reversible with appropriate gut restoration, microbiome support, and dietary management
• The TTG-IgA test that is used to screen for celiac disease will typically be negative in NCGS, because NCGS does not involve the same antibody-mediated mechanism
• Many patients with NCGS can eventually tolerate some wheat products again after thorough gut healing, though individual responses vary

Why the Confusion Exists: These two conditions are often conflated for historical and practical reasons. Before NCGS was formally recognized as a distinct clinical entity, clinicians had only two options: “positive for celiac” or “negative for celiac, no problem.” Patients who clearly reacted to gluten but tested negative were often told their symptoms were functional, psychosomatic, or simply not medically significant.

Research published over the past two decades has gradually established NCGS as a real, biologically distinct condition with identifiable mechanisms and measurable clinical impacts (Catassi et al., 2013; Volta et al., 2015). The challenge is that this research has not yet fully penetrated routine clinical practice, and many physicians, including specialists, still treat both conditions the same way.

From a functional medicine standpoint, the distinction between these two conditions is one of the first things we clarify when a patient presents with symptoms that might involve gluten. Getting that distinction right shapes everything that follows.

The Adaptive Immune Response in Celiac Disease: A Permanent Biological War

Understanding the Adaptive Immune System

To understand what happens in celiac disease, you need to understand the difference between the two major branches of the immune system. The innate immune system is the first responder. It is non-specific, fast, and does not require prior exposure to a pathogen to mount a response. It recognizes broad categories of danger signals and responds immediately with inflammation, phagocytosis, and the release of inflammatory mediators.

The adaptive immune system is the second responder. It develops slowly but is exquisitely specific. When the adaptive immune system encounters a foreign antigen, it takes days to weeks to mount a full response, but when it does, it creates immunological memory. It deploys B cells that produce highly specific antibodies against the antigen’s exact molecular signature, and it activates T cells trained to recognize and destroy cells displaying that antigen. Once the adaptive immune system has learned to recognize a target, that memory is essentially permanent. This is the principle behind vaccination, but it is also the mechanism that makes celiac disease a lifelong condition.

How Celiac Disease Hijacks the Adaptive Immune System

In celiac disease, the adaptive immune system is trained to respond to gluten-related peptides, specifically a complex that forms between gliadin (a component of gluten) and tissue transglutaminase (TTG), an enzyme found throughout the body. The details of how this response develops, involving antigen presentation through HLA-DQ2 and HLA-DQ8 molecules, T cell activation, and B cell antibody production, represent one of the most well-characterized autoimmune mechanisms in all of medicine.

The key features of this adaptive immune response are:

• Specificity: The immune system has created antibodies that target the exact molecular signature of TTG-gliadin complexes
• Memory: The B cells and T cells that produce this response are long-lived memory cells; they persist in the body for years or decades
• Self-targeting: Because TTG is an enzyme that exists throughout the body’s own tissues, including the intestinal villi, the endothelium of blood vessels, and the skin, the antibodies that target TTG-gliadin complexes end up attacking the body’s own tissues
• Permanence: There is no way to “re-educate” the adaptive immune system once this response is established; the only management strategy is to eliminate the trigger permanently

The Role of HLA-DQ2 and HLA-DQ8

Genetics is one of the most important pieces of the celiac puzzle. Approximately 95% of celiac disease patients carry the HLA-DQ2 gene variant, and most of the remaining 5% carry HLA-DQ8. These gene variants determine how the immune system’s antigen-presenting cells display peptides to T cells. Specifically, HLA-DQ2 and DQ8 are particularly good at presenting deamidated gliadin peptides to CD4+ T helper cells, and this presentation is what kicks off the adaptive immune cascade that leads to celiac disease.

However, it is critically important to understand that carrying HLA-DQ2 or HLA-DQ8 does not guarantee celiac disease. Approximately 30% to 40% of the general population carries one of these variants, but only about 1% to 3% develop celiac disease (Sollid & Lie, 2005). This means that genetic susceptibility is necessary but not sufficient. Environmental factors, gut microbiome composition, timing of first gluten exposure, and the cumulative burden of gut insults over time- what I describe using the bucket analogy later in this post- all play critical roles in determining whether the genetic predisposition ever translates into active disease.

What the Adaptive Immune Response Destroys

The targets of the autoimmune attack in celiac disease are not random. They are, tragically, some of the most functionally important tissues in the body:

• Intestinal villi: The finger-like projections that line the small intestine and are responsible for nutrient absorption. When these are flattened and destroyed, which is referred to as villous atrophy, the absorptive surface area of the gut is dramatically reduced, leading to malabsorption of virtually every major nutrient
• Endothelium: The lining of blood vessels. Endothelial tissue transglutaminase is a target of autoantibodies in celiac disease, contributing to cardiovascular complications including endothelial dysfunction and increased atherosclerotic risk.
• Skin: Dermal tissue transglutaminase, particularly epidermal transglutaminase (TG3), is the primary antigen in dermatitis herpetiformis, the skin manifestation of celiac disease

This is why I emphasize so strongly that untreated celiac disease is not merely an inconvenience or a digestive nuisance. It is a progressive autoimmune disease that can cause irreversible damage to multiple organ systems when the dietary trigger is not removed.

The Innate Immune Response in NCGS: Irritation, Not Destruction

The Innate Immune System: Biology’s First Line of Defense

The innate immune system operates on a fundamentally different principle from the adaptive system. Rather than recognizing the specific molecular signature of a particular antigen, the innate immune system recognizes broad categories of molecular patterns that signal danger. These include pathogen-associated molecular patterns (PAMPs) from bacteria, viruses, and fungi, and damage-associated molecular patterns (DAMPs) released by stressed or dying host cells.

The innate immune system operates through a range of cell types including macrophages, neutrophils, dendritic cells, natural killer cells, and mast cells, as well as through pattern recognition receptors such as Toll-like receptors (TLRs). Its responses are fast, often triggered within minutes to hours of exposure, and they do not require prior sensitization. This is why innate immune responses do not create immunological memory or become more precise over time: the innate system is a blunt instrument, effective for rapid containment but not for the exquisitely targeted response the adaptive system eventually mounts.

How Wheat Components Activate the Innate Immune System in NCGS

In non-celiac gluten sensitivity, the immune response is driven primarily by the innate system, and the molecular triggers differ somewhat from those in celiac disease. Current research points to at least three major components of wheat that can activate innate immune responses:

Gliadin peptides can directly activate epithelial cells and immune cells in the gut lining through TLR2 and TLR4 signaling, independent of the adaptive immune response that drives celiac disease. Gliadin also stimulates the release of zonulin, a protein that regulates intestinal permeability, contributing to the leaky gut phenomenon even in NCGS, though through a somewhat different downstream mechanism (Fasano, 2012).

Amylase trypsin inhibitors (ATIs) are wheat proteins that function as natural pesticides in the plant, protecting wheat seeds from insects and predators. In humans, ATIs potently activate TLR4 on macrophages and dendritic cells in the gut, triggering the release of pro-inflammatory cytokines including TNF-alpha, IL-8, and MIP-1-alpha (Junker et al., 2012). Some researchers have argued that ATIs, rather than gliadin per se, may be the primary driver of innate immune activation in NCGS, which would explain why some patients with NCGS can tolerate ancient wheat varieties like einkorn that are low in ATIs but cannot tolerate modern high-yield wheat that has been selectively bred for high ATI content.

Fructans are fermentable oligosaccharides found in wheat, along with many other foods, that can cause significant digestive symptoms in people with irritable bowel syndrome (IBS) and intestinal sensitivity. While fructans are technically a FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) rather than an immunological trigger, their contribution to wheat-related symptoms in sensitive individuals is well documented (Skodje et al., 2018). This means that for some patients who believe they have a gluten-related disorder, the actual culprit may be fructan intolerance rather than true immune sensitivity to gluten itself.

The Clinical Picture of NCGS

The symptoms of NCGS can be remarkably similar to those of celiac disease, which is part of why they are so often confused. Patients may experience:

• Abdominal pain, bloating, and altered bowel habits following gluten exposure
• Fatigue and brain fog that clears when gluten is removed from the diet
• Headaches and migraine-like symptoms
• Joint and muscle pain
• Skin rashes that are different in character from the IgA-mediated dermatitis herpetiformis of celiac disease
• Anxiety, depression, and mood disturbances, which are increasingly recognized as potential manifestations of gut-brain axis disruption in NCGS
• Numbness or tingling in the extremities, which may reflect involvement of the enteric nervous system and gut-brain axis

Clinically, NCGS differs from celiac disease by the absence of serological markers (negative TTG-IgA and EMA tests), the absence of HLA-DQ2/DQ8 genetic markers in many cases, the absence of intestinal villous atrophy on biopsy, and the potential for reversibility with appropriate gut-healing interventions.

The Architecture of the Small Intestine: Why One Cell Layer Matters So Much

Form Follows Function: The Design of the Small Intestinal Mucosa

The small intestine is one of the most architecturally elegant structures in the human body. It faces a nearly impossible challenge: it must allow essential nutrients from the external environment to pass into the body’s internal environment while simultaneously preventing bacteria, toxins, undigested proteins, and other potentially dangerous molecules from doing the same. The precision with which this organ performs this function under normal conditions is extraordinary, and understanding its architecture helps explain why disruption of that architecture has such far-reaching consequences.

The small intestine is approximately six meters long in the average adult, but three levels of anatomical specialization dramatically expand its effective absorptive surface area. The first level is the circular folds or plicae circulares, large folds of the mucosa and submucosa that run perpendicular to the long axis of the intestine. The second level is the villi, finger-like projections of the mucosa that extend into the intestinal lumen and are covered with absorptive epithelial cells called enterocytes. The third level is the microvilli, tiny brush-like projections on the surface of each enterocyte that form the brush border. Together, these three levels of specialization increase the effective absorptive surface area of the small intestine to approximately 250 square meters, roughly the size of a tennis court.

This extraordinary surface area is maintained by just one single layer of epithelial cells. The intestinal epithelium is, as I often describe it to patients, a one-cell-thick filter between the outside world and the inside of the body. A system of protein complexes maintains the structural integrity of that single-cell layer, the most important of which, for our purposes, are tight junctions.

Tight Junctions: The Molecular Glue of the Gut Barrier

Tight junctions are multiprotein complexes located at the apical (lumen-facing) end of the lateral borders between adjacent enterocytes. They function as the primary seal between cells, preventing molecules from passing between cells (the paracellular route) except when the tight junctions are deliberately opened in a regulated fashion. The main structural proteins that make up tight junctions include occludin, claudins (a family of approximately 27 proteins), and junctional adhesion molecules (JAMs). These proteins interact with cytoplasmic scaffolding proteins, including zonula occludens (ZO) proteins ZO-1, ZO-2, and ZO-3, which in turn connect the tight junction complex to the cell’s actin cytoskeleton.

Under normal circumstances, tight junctions maintain selective permeability: they allow water, ions, and very small molecules to pass between cells in a regulated way, but they prevent the passage of large molecules,s including intact proteins and bacterial products. This selectivity is dynamically regulated by signaling molecules, inflammatory mediators, and, critically for our discussion, by a protein called zonulin.

Zonulin: The Master Regulator of Intestinal Permeability

Dr. Alessio Fasano and his colleagues at the University of Maryland first described zonulin as the physiological regulator of tight junction permeability in the human gut (Fasano et al., 2000). Zonulin is the only known physiological molecule in humans that can reversibly modulate intestinal tight junctions, and its dysregulation is now recognized as a central mechanism in the development of what is commonly called leaky gut, or, more precisely, increased intestinal permeability.

Zonulin is released from intestinal epithelial cells in response to certain triggers, the most potent of which include bacterial colonization of the small intestine (particularly with Gram-negative bacteria) and gliadin exposure. When zonulin binds to its receptor on the enterocyte surface, it activates an intracellular signaling cascade involving the epidermal growth factor receptor (EGFR) and PAR2, leading to phosphorylation and internalization of tight junction proteins and effectively opening the paracellular spaces between cells.

This process is normally temporary and self-limiting. But in conditions of chronic gliadin exposure, dysbiosis, or persistent intestinal inflammation, zonulin release can become chronically elevated, keeping tight junctions persistently open and allowing a steady stream of luminal contents, including bacteria, bacterial endotoxins (particularly lipopolysaccharide or LPS), undigested proteins, and other immunogenic molecules,s to enter the lamina propria and ultimately the systemic circulation.

The Absorptive Function of Intestinal Villi

The villi themselves are the workhorses of nutrient absorption. Each villus contains a central lacteal (a lymphatic vessel) and a capillary network, and is covered by thousands of enterocytes whose brush border contains the digestive enzymes responsible for the final breakdown of nutrients. The enterocytes absorb:

• Amino acids and small peptides from protein digestion
• Monosaccharides from carbohydrate digestion
• Fatty acids and monoglycerides from fat digestion, which are packaged into chylomicrons and absorbed via the lacteal
• Vitamins including fat-soluble vitamins A, D, E, and K, as well as water-soluble vitamins including B12, folate, and vitamin C
• Minerals including iron, calcium, magnesium, zinc, and selenium

When the immune attack of celiac disease destroys the villi, this entire absorptive apparatus is compromised. The condition is called villous atrophy, and it is graded on the Marsh scale from 0 (normal) to 3c (complete villous atrophy). The degree of villous atrophy correlates with malabsorption severity and the risk of long-term complications.

Gliadin, Zonulin, and the Leaky Gut Cascade: How the Gut Barrier Breaks Down

The Molecular Identity of Gliadin

Gliadin is one of the two main protein fractions of gluten, the storage protein complex found in wheat (along with related proteins in barley and rye). Gluten consists of approximately equal parts gliadin (the alcohol-soluble fraction) and glutenin (the water-insoluble fraction). The gliadin fraction is the primary immunological troublemaker in both celiac disease and NCGS.

Gliadin is a proline- and glutamine-rich protein, which means it is highly resistant to complete digestion by the digestive enzymes of the human gastrointestinal tract. The human gut was not designed to break down these proteins fully; they survive digestion as incompletely degraded peptide fragments. Under normal circumstances, with an intact intestinal barrier, these peptide fragments remain in the gut lumen and are eventually excreted. The problem begins when the gut barrier is compromised, and these peptides gain access to the tissue beneath the epithelium.

Gliadin has been shown to directly stimulate zonulin release from intestinal epithelial cells, an effect mediated through the CXCR3 receptor on the enterocyte surface, regardless of whether the individual has celiac disease (Fasano, 2012). This means gliadin can increase intestinal permeability in virtually anyone, not just those genetically susceptible to celiac disease. However, the degree and consequences vary widely based on genetic background, microbiome composition, and baseline gut health.

The Step-by-Step Cascade of Gut Barrier Breakdown

The sequence of events that leads from gliadin exposure to a state of increased intestinal permeability follows a relatively well-defined molecular pathway:

Step 1: Gliadin arrives in the small intestine. After ingestion of gluten-containing food, digestion in the stomach and proximal small intestine breaks gluten down into component proteins, including gliadin peptides. These peptides are not fully digested and enter the small intestinal lumen as intact immunogenic fragments.

Step 2: Gliadin binds to CXCR3 receptors on enterocytes. Gliadin peptides interact with the CXCR3 chemokine receptor on the surface of intestinal epithelial cells. This binding triggers zonulin release from enterocytes into the intestinal lumen and bloodstream.

Step 3: Zonulin opens the tight junctions. Zonulin binds to its receptor (protease-activated receptor 2, or PAR2) on neighboring enterocytes and activates an intracellular signaling cascade that phosphorylates and internalizes tight junction proteins, including occludin and ZO-1. The tight junctions open, creating paracellular gaps.

Step 4: Luminal contents cross the epithelial barrier. With the tight junctions open, a wide range of luminal contents can now cross the epithelial barrier through the paracellular route. This includes:

• Intact gliadin peptides and other incompletely digested proteins
• Bacterial products including lipopolysaccharide (LPS) from Gram-negative bacteria
• Bacterial DNA and fragments
• Other environmental antigens and toxins

Step 5: The immune system encounters these contents in the lamina propria. The lamina propria, the connective tissue layer beneath the epithelium, is densely populated with immune cells including dendritic cells, macrophages, T lymphocytes, and B lymphocytes. When these cells encounter the bacterial products and gliadin peptides that have crossed the leaky epithelial barrier, they mount an immune response. LPS, in particular, potently activates the innate immune system through TLR4, triggering the release of pro-inflammatory cytokines including TNF-alpha, IL-1beta, IL-6, and IL-8.

Step 6: Inflammation further disrupts the barrier. The inflammatory cytokines released by the activated immune cells in the lamina propria themselves further disrupt tight junction integrity, creating a vicious cycle in which increased permeability leads to immune activation, which leads to more inflammation, which leads to more permeability. Once established, this cycle tends to self-perpetuate unless you remove the inciting dietary trigger and take active steps to restore the gut barrier.

Why This Matters Beyond the Gut

The cascade I have just described does not stay confined to the gut. Once bacteria, bacterial products, and immunogenic food proteins enter the systemic circulation through a chronically leaky gut, they can trigger immune activation and inflammation throughout the body. This is the mechanism by which gut barrier dysfunction contributes to conditions as diverse as rheumatoid arthritis, multiple sclerosis, type 1 diabetes, psoriasis, cardiovascular disease, depression, and anxiety.

Clinically, this means a patient presenting with joint pain, a skin condition, a mood disorder, or a cardiovascular risk profile may have a gut barrier problem at the root of their systemic inflammation, even if their gastrointestinal symptoms are minimal or absent. I see this pattern regularly in practice, and it is one reason gut health assessment is a central pillar of the functional medicine evaluation we perform at Injury Medical Clinic PA.

Tissue Transglutaminase and Molecular Mimicry: When the Immune System Attacks Itself

What Is Tissue Transglutaminase?

Tissue transglutaminase (TTG, also written as tTG or TG2) is an enzyme that belongs to the transglutaminase family, a group of enzymes that catalyze the formation of covalent cross-links between proteins. TTG is found throughout the body, both intracellularly and extracellularly, and it plays important roles in:

• Extracellular matrix stabilization: TTG cross-links proteins in the extracellular matrix, contributing to tissue integrity and wound healing
• Apoptosis: TTG is involved in the regulation of programmed cell death
• Intracellular signaling: TTG participates in various intracellular signaling cascades involving G proteins and kinases
• Fibrin stabilization: TTG (in the form of Factor XIIIa in the coagulation cascade) cross-links fibrin, stabilizing blood clots

In the context of celiac disease, TTG plays a pivotal dual role. On one hand, it deamidates gliadin peptides, converting specific glutamine residues to glutamate, which dramatically increases their affinity for HLA-DQ2 and HLA-DQ8 molecules and thus their immunogenicity. On the other hand, TTG is itself a target of the autoimmune response that results from this deamidation, making it both a perpetrator and a victim in the celiac disease story.

The Formation of TTG-Gliadin Complexes

When gliadin peptides cross the leaky intestinal barrier and enter the lamina propria, they immediately encounter TTG in the extracellular matrix. TTG performs its enzymatic function on gliadin, deamidating specific glutamine residues and, in some cases, covalently cross-linking gliadin molecules to TTG itself, forming TTG-gliadin complexes. These complexes are the proximate immunological trigger for celiac disease.

The TTG-gliadin complexes are taken up by antigen-presenting cells (APCs), particularly dendritic cells and B cells expressing TTG on their surface, processed into peptide fragments, and presented on HLA-DQ2 or HLA-DQ8 molecules to CD4+ T helper cells in the lamina propria. This T cell activation initiates the adaptive immune response in celiac disease.

The activated T helper cells release cytokines that drive:

• B cell activation and class switching, resulting in the production of anti-TTG IgA and IgG antibodies
• CD8+ cytotoxic T cell activation, which directly kills enterocytes displaying stress signals on their surface
• Innate immune amplification through the release of IL-15, which is a master cytokine in the pathogenesis of celiac disease

Molecular Mimicry: Why the Immune System Cannot Tell the Difference

Molecular mimicry is central to understanding why celiac disease is autoimmune. Molecular mimicry refers to the phenomenon in which antibodies or T cells generated against a foreign antigen (in this case, a gliadin-TTG complex) also react against a self-antigen (in this case, TTG itself and other structurally similar proteins in the body’s own tissue).

The reason the anti-TTG antibodies generated in celiac disease attack the body’s own tissues is straightforward: the immune system is producing antibodies against the TTG component of the TTG-gliadin complex, and TTG is a protein that the body makes. When these antibodies circulate through the bloodstream and encounter TTG in the tissues where it naturally exists, they bind to it and trigger immune destruction of that tissue. This is the autoimmune component of celiac disease.

The tissues where TTG is most highly expressed and where the autoimmune attack is therefore most destructive include:

• Intestinal epithelium: The enterocytes and the extracellular matrix of the intestinal villi contain abundant TTG, making them prime targets for autoimmune destruction
• Vascular endothelium: Blood vessel linings contain significant TTG, contributing to the cardiovascular complications of celiac disease
• Skin (epidermal transglutaminase, TG3): The skin contains a closely related transglutaminase isoform that is targeted by IgA antibodies in dermatitis herpetiformis, the skin manifestation of celiac disease
• Neurological tissue: TG6, another transglutaminase isoform expressed in the brain and nervous system, is the target of autoantibodies in gluten ataxia, a neurological manifestation of celiac disease

Cross-Reactivity With Dairy: The Casein-Gliadin Connection

One of the most clinically important and least discussed aspects of celiac disease management is the cross-reactivity between gluten and dairy proteins, specifically between gliadin and casein, the primary protein in cow’s milk. This cross-reactivity occurs through the mechanism of molecular mimicry: the immune system’s antibodies and T cells that are directed against gliadin peptides can also recognize structurally similar sequences in casein, because certain peptide sequences in gliadin and casein share enough structural similarity to be recognized by the same immune receptors.

The research literature has well-established casein cross-reactivity. A study by Vojdani and Tarash (2013) showed that antibodies raised against alpha-gliadin showed significant immunoreactivity against casein and other milk proteins, as well as multiple human tissue antigens, providing direct evidence of molecular mimicry between wheat and dairy proteins and human tissue.

This has direct and important clinical implications. Patients with celiac disease who eliminate gluten but continue to consume dairy products may continue to experience immune activation, ongoing intestinal inflammation, and persistent symptoms, not because of gluten exposure but because their immune system’s anti-gliadin antibodies are cross-reacting with casein. This is one of the primary reasons I recommend that patients with confirmed celiac disease eliminate both gluten and dairy, at least initially, and one reason I bring up this connection every time I discuss celiac disease management.

IgA and IgG Antibodies in Celiac Disease: The Mechanism of Self-Destruction

A Brief Immunology Primer on Antibody Classes

To understand the specific damage mechanisms in celiac disease, it helps to understand the two most relevant antibody classes: IgA and IgG.

IgA is the predominant antibody class in mucosal secretions, including the secretions lining the intestinal tract, the respiratory tract, and other mucosal surfaces. In its secretory form (sIgA), it exists as a dimer. It plays a critical role in mucosal immunity, neutralizing pathogens and antigens at the mucosal surface before they can cross the epithelial barrier. Serum IgA is a monomer and constitutes approximately 15% to 20% of serum immunoglobulins. In celiac disease, the immune system produces anti-TTG IgA antibodies, the primary serological marker used for diagnosis.

IgG is the most abundant antibody class in the blood and interstitial fluids. It is the primary antibody of the secondary immune response and provides long-term immunological memory. IgG antibodies can cross the placenta, providing passive immunity to the fetus. In celiac disease, anti-TTG IgG and anti-deamidated gliadin peptide (anti-DGP) IgG antibodies are produced. They are particularly useful diagnostically in patients who are IgA-deficient (a condition that occurs in approximately 2% to 3% of celiac disease patients and can cause false-negative TTG-IgA test results).

How These Antibodies Cause Tissue Damage

The anti-TTG IgA antibodies produced in celiac disease are not passive markers; they actively contribute to the tissue destruction that characterizes the disease. Several mechanisms have been identified through which these antibodies cause damage:

Direct binding to enterocytes and the extracellular matrix: Anti-TTG IgA antibodies bind to TTG expressed on the surface of enterocytes and in the extracellular matrix of the intestinal villi. This binding triggers complement activation, which can directly lyse cells, and antibody-dependent cellular cytotoxicity (ADCC), in which natural killer cells and macrophages recognize the antibody-coated cells and destroy them.

Disruption of TTG function: TTG performs important functions in the extracellular matrix, including cross-linking proteins that maintain the structural integrity of the villous architecture. When anti-TTG antibodies bind to and inhibit TTG, they interfere with these structural functions, contributing to the villous atrophy that characterizes celiac disease.

Activation of mast cells and eosinophils: IgA antibodies can activate mast cells and eosinophils in the intestinal mucosa, triggering the release of histamine, proteases, and other inflammatory mediators that further damage the epithelial barrier.

Systemic effects via the bloodstream: In a leaky gut, IgA-gliadin complexes (antibody-antigen complexes formed when anti-gliadin IgA antibodies bind to gliadin peptides that have crossed the leaky barrier and entered the bloodstream) circulate throughout the body and can deposit in various tissues. As I will discuss in the next section, their deposition in the dermal papillae is the primary mechanism of dermatitis herpetiformis.

The TTG-IgA Test: The Gold Standard Serological Screen

The TTG-IgA test (anti-tissue transglutaminase IgA) is the single most sensitive and specific serological test for celiac disease screening. Current guidelines from the American College of Gastroenterology (ACG) and the British Society of Gastroenterology (BSG) recommend TTG-IgA as the first-line serological test for celiac disease (Rubio-Tapia et al., 2023).

The diagnostic performance of the TTG-IgA test is impressive:

• Sensitivity: approximately 95% to 98% in patients who are not IgA-deficient and are on a regular gluten-containing diet
• Specificity: approximately 95% to 97%

However, as I emphasize to every patient, these performance characteristics are only valid if the patient has been consuming a regular gluten-containing diet for an adequate period of time before the test. The standard recommendation is at least 4 weeks of regular gluten consumption (a gluten challenge) before testing. Some guidelines recommend up to 8 to 12 weeks for patients who have been strictly gluten-free for a prolonged period.

The reason is straightforward: the anti-TTG IgA antibodies the test measures are produced in direct response to ongoing gluten exposure and the immune activation it triggers. When a patient eliminates gluten from their diet, the immunological stimulus for antibody production is removed, and antibody titers gradually decline over weeks to months. If a patient has been gluten-free for 3 months before testing, the TTG-IgA test will almost certainly be negative, regardless of whether they have celiac disease, because antibody levels have dropped below the detectable threshold. This creates a false-negative result that can reassure a patient and delay or prevent an accurate diagnosis.

This is a critically important clinical point that, regrettably, is not always communicated to patients before testing. I have seen patients in my practice who went gluten-free based on self-diagnosis, felt better, then sought formal testing only to be told they tested negative and therefore did not have celiac disease. Interpreting that result correctly requires knowing how long the patient had been gluten-free before testing. Without that context, the negative result is nearly meaningless.

Dermatitis Herpetiformis: When Gluten Shows Up on Your Skin

The Skin as a Window Into Gut Immune Dysfunction

One of the most dramatic and, for patients, often most distressing manifestations of celiac disease has nothing to do with the gut. Dermatitis herpetiformis (DH) is the skin manifestation of celiac disease, and it clearly illustrates how the autoimmune processes triggered by gluten in the gut can have consequences far from the intestine.

Dermatitis herpetiformis is characterized by intensely pruritic (itchy) papulovesicular lesions, meaning small blisters and red bumps, that typically appear on the extensor surfaces of the elbows, knees, buttocks, and back. However, they can appear anywhere on the body. The lesions tend to be symmetrically distributed and are extraordinarily itchy, often described by patients as one of the most intensely uncomfortable sensations they have ever experienced. The combination of burning, stinging, and itching associated with DH lesions can be debilitating.

Clinicians often initially misdiagnose the condition as eczema, psoriasis, or contact dermatitis, and patients may spend years receiving topical steroid treatments that temporarily suppress symptoms without addressing the underlying cause. A correct diagnosis of DH requires a skin biopsy, ideally from perilesional (adjacent to a lesion rather than from the lesion itself) skin, showing characteristic IgA deposition in the dermal papillae.

The Immunological Mechanism of DH

Celiac disease produces skin lesions through IgA-gliadin immune complexes that form when anti-gliadin IgA antibodies in the bloodstream bind to gliadin peptides that have leaked across the damaged intestinal barrier. These complexes circulate in the bloodstream and, for reasons that are not yet fully understood, have a predilection for depositing in the dermal papillae, the small projections of the dermis that interdigitate with the epidermis, particularly in the extensor skin.

Once deposited in the dermal papillae, the IgA-containing immune complexes activate the complement system and trigger neutrophil recruitment. Neutrophil influx and complement activation lead to local tissue damage, mast cell degranulation, and release of inflammatory mediators, including histamine, proteases, and prostaglandins. This inflammatory cascade produces the characteristic papulovesicular lesions of DH.

The critical insight here is that DH is a manifestation of systemic IgA-mediated autoimmunity driven by gut-derived immune activation. The skin lesions will not resolve with topical treatment alone; the only definitive treatment is eliminating the dietary trigger, gluten, and often dairy as well, given the cross-reactivity discussed earlier. Dapsone can provide relatively rapid relief of skin symptoms, but it does not address the underlying autoimmune process or protect the intestine from ongoing damage.

Mast Cell Degranulation: The Inflammatory Amplifier

Mast cells are tissue-resident immune cells that are loaded with preformed inflammatory mediators stored in granules. They are found in high concentrations in the skin, intestinal mucosa, respiratory mucosa, and connective tissues. When mast cells are activated, whether by IgE-mediated mechanisms (as in allergic reactions), IgA-mediated mechanisms (as in DH), complement activation, or direct cellular stress, they undergo degranulation: the rapid release of their stored mediators, including histamine, tryptase, chymase, heparin, leukotrienes, and prostaglandins.

In the context of celiac disease and DH, mast cell degranulation in the skin contributes to:

• Vasodilation and increased vascular permeability, causing the redness and swelling of skin lesions
• Pruritus (itching), primarily mediated by histamine acting on sensory nerve endings
• Blister formation, as increased vascular permeability allows fluid to accumulate in the dermal-epidermal junction area
• Pain and burning, mediated by inflammatory prostaglandins and nerve sensitization

In the intestinal mucosa, mast cell degranulation similarly contributes to the local inflammatory environment, further disrupting the epithelial barrier and amplifying the immune response.

Eating Right to Feel Better-Video

Cytokine Overload, Adrenal Exhaustion, and Liver Stress: The Systemic Fallout

The Cytokine Storm of Chronic Immune Activation

When the immune system fights a battle, it releases an enormous array of chemical signaling molecules called cytokines. In acute infection or injury, this cytokine response is carefully orchestrated, proportionate to the threat, and self-limiting. The immune system mounts its response, neutralizes the threat, and then stands down, with anti-inflammatory cytokines and regulatory T cells restoring homeostasis.

In celiac disease and, to a lesser extent, in NCGS, this process is not self-limiting because the immunological trigger, dietary gluten, is being continuously reintroduced. Every meal containing gluten is another stimulus for immune activation, another round of cytokine production, another wave of tissue-damaging inflammation. The result is a state of chronic low-grade systemic inflammation driven by cytokines that include:

• TNF-alpha (tumor necrosis factor-alpha): Promotes inflammation, increases intestinal permeability, stimulates muscle catabolism (contributing to the muscle wasting sometimes seen in severe celiac disease), and activates the hypothalamic-pituitary-adrenal (HPA) axis.
• IL-1beta (interleukin-1-beta): A potent pro-inflammatory cytokine that activates the HPA axis, promotes fever, and contributes to insulin resistance.e
• IL-6: Both pro-inflammatory and modulatory in function; chronically elevated IL-6 is associated with fatigue, depression, and disruption of the circadian rhythm
• IL-15: A particularly important cytokine in celiac disease pathogenesis; IL-15 promotes the survival and cytotoxic activation of intraepithelial lymphocytes, which are responsible for direct killing of enterocytes
• IFN-gamma (interferon-gamma): A pro-inflammatory cytokine that increases intestinal permeability by disrupting tight junction protein expression and activates macrophages

The sustained elevation of these cytokines over months and years has consequences that extend far beyond the gut, affecting virtually every organ system in the body.

Adrenal Exhaustion: The HPA Axis Under Siege

The hypothalamic-pituitary-adrenal (HPA) axis is the body’s primary stress response system. When the brain perceives a threat, whether physical, psychological, or immunological, the hypothalamus releases corticotropin-releasing hormone (CRH), which stimulates the pituitary to release adrenocorticotropic hormone (ACTH), which in turn stimulates the adrenal cortex to produce cortisol. Cortisol is the body’s primary anti-inflammatory hormone; it suppresses immune activation, mobilizes energy stores, and helps the body cope with stress.

The problem with chronic systemic inflammation driven by celiac disease or severe NCGS is that elevated IL-1beta, IL-6, and TNF-alpha levels continuously stimulate the HPA axis. Over time, this chronic HPA activation leads to:

• Cortisol dysregulation: Initially, cortisol levels may be chronically elevated, contributing to symptoms including insomnia, anxiety, central weight gain, and immune suppression. Over time, the HPA axis may become dysregulated, with blunted cortisol responses and disrupted diurnal cortisol rhythms.
• Adrenal fatigue or HPA axis dysfunction: While “adrenal fatigue” as a diagnostic category is debated in conventional medicine, HPA axis dysregulation secondary to chronic inflammation is a well-documented phenomenon. Patients experience profound fatigue, difficulty recovering from stress, disrupted sleep, and a general sense of physical exhaustion that does not improve with rest.
• Immune suppression paradox: Chronically elevated cortisol is itself immunosuppressive, which means that patients with severe, long-standing celiac disease may have both an overactive autoimmune process driving their celiac disease and a paradoxically suppressed ability to mount effective responses to infections.

Liver Stress: The Detoxification Burden

The liver is the body’s primary detoxification organ, and it is also the first organ to receive the blood draining from the intestinal tract via the portal vein. This means that every toxic or immunogenic molecule that leaks across the damaged intestinal barrier in celiac disease or NCGS is delivered directly to the liver before it reaches the systemic circulation.

The liver responds to this increased load in several ways:

• Increased Kupffer cell activation: The liver’s resident macrophages, Kupffer cells, are activated by the LPS and other bacterial products arriving from the leaky gut. This activation drives hepatic inflammation and reactive oxygen species production.
• Elevated liver enzymes: The medical literature documents that a significant proportion of patients with celiac disease have mildly to moderately elevated liver enzymes, particularly alanine aminotransferase (ALT) and aspartate aminotransferase (AST), reflecting this hepatic inflammation. This pattern, sometimes called celiac hepatitis or cryptogenic hepatitis, often resolves completely with strict adherence to a gluten-free diet (Rubio-Tapia & Murray, 2007).
• Impaired detoxification capacity: When the liver is chronically stressed by the increased load of gut-derived toxins and immune complexes, its capacity to perform its normal detoxification functions, including phase I and phase II biotransformation of environmental toxins, metabolic waste products, and hormones, may be compromised.

The Role of Integrative Chiropractic Care in Managing Systemic Inflammation

This is a natural point to introduce the role of integrative chiropractic care in managing the systemic inflammatory burden associated with gluten-related disorders. While chiropractic care cannot directly eliminate the autoimmune process or repair the gut barrier, it plays an important and well-supported role in the broader clinical picture through several mechanisms:

Neurological modulation of the immune system: The nervous and immune systems communicate bidirectionally. The autonomic nervous system, particularly the vagus nerve, strongly regulates immune function through the cholinergic anti-inflammatory pathway. Stimulation of the vagus nerve reduces the production of pro-inflammatory cytokines, including TNF-alpha, IL-1beta, and IL-6. Chiropractic adjustments, particularly those targeting the cervical and thoracic spine, have been shown in research to modulate autonomic nervous system tone and may enhance vagal anti-inflammatory activity (Welch & Boone, 2008).

Reduction of mechanical stress on the nervous system: Vertebral subluxations, abnormal joint mechanics, and motion restriction in the spine can create mechanical stress on the nervous system that contributes to chronic pain signaling and sympathetic nervous system over-activation. Chronic sympathetic over-activation suppresses immune regulation and promotes a pro-inflammatory state. By restoring normal spinal mechanics and reducing the nervous system’s mechanical burden, chiropractic care may help shift the autonomic balance away from sympathetic dominance and toward the parasympathetic, anti-inflammatory state that supports healing.

Addressing musculoskeletal consequences of malnutrition: The nutrient malabsorption that accompanies untreated celiac disease has direct musculoskeletal consequences. Calcium and vitamin D malabsorption reduces bone density and increases fracture risk. Magnesium malabsorption contributes to muscle cramping, spasm, and pain. Vitamin K malabsorption affects bone matrix protein synthesis. Zinc and B-vitamin deficiencies affect connective tissue integrity and nerve function. Chiropractic care, integrated with nutritional assessment and supplementation guided by functional medicine principles, directly addresses these musculoskeletal manifestations.

Intestinal Villi Destruction and Nutrient Malabsorption: Why You Cannot Supplement Your Way Out

The Anatomy of Villous Atrophy

As I described in the section on small intestinal architecture, the intestinal villi are the primary structures responsible for nutrient absorption in the small intestine. In celiac disease, the autoimmune attack on the intestinal epithelium causes progressive flattening and eventual complete loss of the villi, a condition called villous atrophy. This is assessed histologically on biopsies taken from the duodenum during upper endoscopy, and it is graded using the modified Marsh classification:

• Marsh 0: Normal intestinal mucosa; no villous abnormality
• Marsh 1: Increased intraepithelial lymphocytes (greater than 25 per 100 enterocytes) with normal villous architecture; found in celiac disease but also in other conditions
• Marsh 2: Increased intraepithelial lymphocytes with crypt hyperplasia but preserved villi
• Marsh 3a: Partial villous atrophy with crypt hyperplasia
• Marsh 3b: Subtotal villous atrophy with crypt hyperplasia
• Marsh 3c: Total villous atrophy with crypt hyperplasia, also called “flat mucosa”; represents the most severe form

As villous atrophy progresses from Marsh 3a to Marsh 3c, the effective absorptive surface area of the small intestine is progressively reduced. In total villous atrophy (Marsh 3c), the absorptive surface area can be reduced to a fraction of normal, with catastrophic consequences for nutrient absorption.

The Specific Nutritional Deficiencies of Untreated Celiac Disease

The pattern of malabsorption in celiac disease is predictable based on small-intestinal anatomy. The duodenum and proximal jejunum, where villous atrophy is typically most severe in celiac disease, are the primary absorption sites for:

Iron: Iron absorption occurs almost exclusively in the duodenum and proximal jejunum, making it one of the first and most severely affected nutrients in celiac disease. Iron deficiency anemia is one of the most common presentations of celiac disease, particularly in adults, and is often the finding that first prompts a celiac workup. The anemia may be microcytic (small red blood cells) due to iron deficiency, macrocytic (large red blood cells) due to folate or B12 deficiency, or mixed.

Calcium and Vitamin D: Calcium absorption is dependent on vitamin D (specifically its active form, calcitriol), and both calcium and vitamin D are primarily absorbed in the duodenum and proximal jejunum. Celiac disease impairs calcium absorption in two ways: directly through villous atrophy and indirectly through impaired vitamin D absorption. The result is hypocalcemia and, over years, osteopenia and osteoporosis. The World Gastroenterology Organization (WGO) recognizes celiac disease as a major risk factor for osteoporosis (WGO, 2016).

Folate: Folate is absorbed primarily in the proximal jejunum, making it highly vulnerable to malabsorption in celiac disease. Folate deficiency causes macrocytic anemia and, in women of childbearing age, significantly increases the risk of neural tube defects in offspring. Folate is also critical for methylation reactions throughout the body, so folate deficiency in celiac disease can have far-reaching metabolic consequences beyond anemia.

Zinc: Zinc is absorbed in the proximal small intestine and is essential for immune function, wound healing, protein synthesis, DNA synthesis, and enzyme activity. Zinc deficiency in celiac disease contributes to impaired immune function (creating a paradox in which the immune system is hyperactive in one dimension, the autoimmune response, while being deficient in another), poor wound healing, growth retardation in children, and reproductive dysfunction.

Magnesium: Magnesium is absorbed throughout the small intestine and is involved in over 300 enzymatic reactions in the body. Magnesium deficiency is extremely common in untreated celiac disease. It contributes to muscle cramps and spasms, fatigue, insomnia, cardiac arrhythmias, and worsening bone density (since magnesium is necessary for proper calcium metabolism).

Fat-soluble vitamins (A, D, E, K): All fat-soluble vitamins require intact fat absorption for their own absorption. Because fat absorption depends on healthy intestinal villi, celiac disease impairs absorption of all four fat-soluble vitamins. Vitamin A deficiency contributes to night blindness, immune dysfunction, and skin problems. Vitamin E deficiency contributes to neurological symptoms. Vitamin K deficiency impairs blood clotting and bone matrix protein synthesis.

Vitamin B12: B12 is absorbed in the terminal ileum through a complex that requires intrinsic factor produced by gastric parietal cells. Although the terminal ileum is typically less affected by celiac disease than the proximal small intestine, B12 deficiency is common because of a combination of factors, including bacterial overgrowth in the small intestine that competes for B12 and potential autoimmune effects on intrinsic factor production. B12 deficiency causes neurological damage, including subacute combined degeneration of the spinal cord, which can be irreversible if not treated promptly.

Why You Cannot Simply Take More Supplements

Patients often ask me whether they can continue eating gluten and take supplements to compensate for the malabsorption. The answer, for celiac disease, is an unequivocal no, and understanding why requires understanding the fundamental problem.

When intestinal villi are severely atrophied, the small intestine’s absorptive capacity is compromised not just for a few specific nutrients but for virtually all nutrients. The enterocytes, the absorptive cells, are either absent or dysfunctional. The enzymes that line the brush border of the enterocytes, including lactase (for dairy digestion), sucrase-isomaltase (for sugar digestion), and peptidases (for protein digestion), are absent or markedly reduced in villous atrophy. The transporters that move specific nutrients across the enterocyte membrane are expressed on the villi and are therefore markedly reduced in number.

If you take an iron supplement when your duodenal villi are flattened by celiac disease, a very small proportion of that iron will be absorbed because there are insufficient functional enterocytes to absorb it. The same problem applies to calcium supplements. Furthermore, if the vitamin D required to facilitate calcium absorption is itself being malabsorbed due to fat malabsorption, the calcium absorption problem is compounded.

The only effective strategy for restoring nutrient absorption in celiac disease is to remove the immunological trigger (gluten, and dairy for cross-reactivity reasons), allow the intestinal villi to regenerate (which they will, given sufficient time on a strict gluten-free diet, typically months to a year or more for adults), and then supplement strategically during the recovery period to address existing deficiencies.

At Injury Medical Clinic PA, our functional medicine approach involves:

• Comprehensive nutritional assessment using advanced laboratory panels that measure functional nutrient status (not just serum levels)
• Targeted supplementation protocols designed to address identified deficiencies during the gut healing phase
• Dietary guidance that optimizes nutrient density within the constraints of a gluten-free and dairy-free protocol
• Monitoring and adjustment of supplement protocols as gut healing progresses and absorptive capacity is restored

Osteoporosis, Neurological Damage, and Cardiovascular Consequences of Untreated Celiac Disease

Osteoporosis: The Silent Long-Term Consequence

Osteoporosis is one of the most serious and underappreciated long-term consequences of untreated or inadequately treated celiac disease. The relationship between celiac disease and bone health is multifactorial, involving:

Calcium and Vitamin D malabsorption: As discussed above, impaired calcium and vitamin D absorption due to villous atrophy primarily drives bone loss in celiac disease. Chronic negative calcium balance stimulates parathyroid hormone (PTH) secretion, which mobilizes calcium from bone by activating osteoclasts (bone-resorbing cells). Over years, this ongoing calcium withdrawal from bone leads to progressive reduction in bone mineral density (BMD).

Inflammatory cytokine-mediated bone loss: The chronic elevation of pro-inflammatory cytokines in untreated celiac disease, particularly TNF-alpha, IL-1beta, IL-6, and RANKL, directly stimulates osteoclast activity and suppresses osteoblast (bone-forming cell) activity. This imbalance between bone resorption and bone formation leads to net bone loss independent of nutritional deficiencies.

Magnesium deficiency: Magnesium is required for the proper function of PTH and for vitamin D activation. Magnesium deficiency in celiac disease therefore compounds the effects of calcium and vitamin D malabsorption on bone health.

Vitamin K2 deficiency: Vitamin K2 is required for the carboxylation of osteocalcin, a protein produced by osteoblasts that is essential for the binding of calcium to the bone matrix. Vitamin K2 deficiency means that even if calcium is available, it cannot be properly incorporated into bone.

The clinical consequence is that patients with undiagnosed or untreated celiac disease have significantly reduced bone mineral density and a markedly increased risk of fragility fractures, including vertebral fractures, hip fractures, and wrist fractures. Studies have shown that celiac disease patients have an approximately 40% increased risk of fractures compared to the general population (Ludvigsson et al., 2012). This risk is substantially reduced but not eliminated with strict adherence to a gluten-free diet and appropriate calcium, vitamin D, and vitamin K2 supplementation.

From a chiropractic standpoint, this has important clinical implications. Patients with unrecognized celiac disease who present for chiropractic care may have significantly reduced bone mineral density, increasing their fracture risk. Our assessment protocols at Injury Medical Clinic PA include screening for nutritional deficiencies and bone health risk factors in patients with chronic musculoskeletal presentations, particularly those with features that might suggest an underlying autoimmune or malabsorptive condition.

Neurological Damage: Gluten and the Nervous System

The neurological consequences of celiac disease are among its most serious and, in some cases, most irreversible manifestations. Gluten neuropathy and gluten ataxia are well-characterized neurological disorders caused by the autoimmune process triggered by gluten in genetically susceptible individuals.

Gluten ataxia is a condition in which the autoimmune process triggered by celiac disease or gluten sensitivity preferentially targets the cerebellum, the brain region responsible for coordination, balance, and fine motor control. Patients present with progressive gait ataxia (unsteady walking), limb ataxia (clumsiness of the arms and hands), and sometimes nystagmus (involuntary eye movements). Anti-TTG antibodies, specifically those directed against TG6 (transglutaminase 6), a transglutaminase isoform expressed in Purkinje cells of the cerebellum, are found in many patients with gluten ataxia. MRI studies may show cerebellar atrophy. Strict adherence to a gluten-free diet can stabilize or partially reverse the neurological damage if initiated early, but advanced cerebellar atrophy may not be reversible.

Gluten peripheral neuropathy presents as a length-dependent peripheral neuropathy, typically causing numbness, tingling, burning pain, and weakness that begins in the feet and lower legs and progresses proximally over time. It may be purely sensory or may involve both sensory and motor components. The mechanism involves autoimmune attack on peripheral nerve tissue, potentially mediated by anti-ganglioside antibodies and anti-TG6 antibodies. Again, a strict gluten-free diet is the primary treatment.

Cognitive effects: Celiac disease can affect cognitive function through multiple mechanisms, including chronic systemic inflammation (neuroinflammation), nutritional deficiencies affecting brain function (particularly B12, folate, zinc, and iron), and potentially direct neurological autoimmunity. Patients with untreated celiac disease frequently report brain fog, difficulty concentrating, memory problems, anxiety, and depression. Many of these cognitive symptoms improve significantly with strict gluten elimination.

Migraine and headache: A higher prevalence of migraine and chronic headache has been documented in celiac disease patients compared to the general population, though the mechanism is not fully established. Proposed mechanisms include cerebrovascular effects of anti-TTG antibodies on the vascular endothelium, neuroinflammation, and nutritional deficiencies affecting serotonin synthesis.

Cardiovascular Consequences: Autoimmunity in the Vessels

The cardiovascular consequences of celiac disease are an area of active research and growing clinical awareness. The endothelium of blood vessels contains tissue transglutaminase, making it a target of the anti-TTG antibodies produced in celiac disease. This endothelial targeting is believed to contribute to:

Endothelial dysfunction: The vascular endothelium plays a critical role in regulating vascular tone, inflammation, and coagulation. Anti-TTG antibodies binding to endothelial TTG impair normal endothelial function by reducing nitric oxide (NO) production, the endothelium’s primary vasodilator. Reduced NO production impairs vasodilation, increases vascular tone, and creates a pro-thrombotic, pro-inflammatory vascular environment.

Accelerated atherosclerosis: The combination of chronic systemic inflammation (with elevated CRP, TNF-alpha, and IL-6), endothelial dysfunction, and nutritional deficiencies (particularly deficiencies in homocysteine-metabolizing B vitamins including B12, B6, and folate, which lead to elevated homocysteine, an independent cardiovascular risk factor) creates conditions that promote atherosclerotic plaque formation.

Dilated cardiomyopathy: There are well-documented case reports and small series of patients with celiac disease who develop dilated cardiomyopathy (a form of heart muscle disease characterized by enlargement and weakening of the heart), which may improve with strict gluten elimination. The proposed mechanism involves anti-heart muscle antibodies that cross-react with TTG in cardiac muscle tissue.

Increased risk of atrial fibrillation: Population-based studies have found that celiac disease is associated with a modestly increased risk of atrial fibrillation, possibly related to electrolyte disturbances (particularly magnesium deficiency) and inflammation affecting the cardiac conduction system.

The Bucket Theory: Understanding Threshold Dynamics and Late-Onset Presentations

Why Does Celiac Disease “Appear” in Adulthood?

One of the most common questions I hear from patients who develop symptoms of celiac disease or gluten sensitivity in their 40s, 50s, or even later is: “Why did this start now? I’ve been eating bread my whole life without any problems.” This is a completely reasonable question, and the answer lies in a concept I call threshold dynamics, which I explain to patients with the bucket analogy.

The delayed onset of gluten-related disorders in genetically susceptible individuals reflects the interaction between a fixed genetic predisposition and a dynamic, accumulating load of gut-disrupting factors over time. The genetic component, the HLA-DQ2 or HLA-DQ8 variant, has been present since birth. But genetics alone does not determine when, or even whether, celiac disease will develop. The timing depends on the cumulative burden of factors that stress the gut microbiome, disrupt the intestinal barrier, and push the immune system toward an inflammatory, autoimmune phenotype.

The Bucket Analogy: A Framework for Understanding Threshold Dynamics

Imagine your gut health as a bucket. This bucket starts relatively empty at birth. Over the course of your life, various factors slowly fill this bucket:

Antibiotic use: Every course of antibiotics, while sometimes medically necessary, disrupts the gut microbiome, reducing microbial diversity and potentially allowing opportunistic pathogens to take hold. The gut microbiome plays a critical role in maintaining intestinal barrier integrity and immune regulation; a dysbiotic microbiome is a weaker barrier.

Dietary factors: A diet high in ultra-processed foods, added sugars, and artificial additives and low in fiber, fermented foods, and diverse plant matter progressively degrades microbiome diversity. Modern wheat varieties, selectively bred for high yield and high gluten content, contain significantly more gliadin and more ATIs than ancient wheat varieties, adding to the gut’s immunological burden with every meal.

Medications: Beyond antibiotics, many commonly used medications disrupt the gut barrier. NSAIDs (ibuprofen, naproxen) increase intestinal permeability. Proton pump inhibitors (PPIs) reduce gastric acid, impairing the first line of defense against oral pathogens and altering the small intestinal microbiome. Oral contraceptives have been associated with alterations in gut microbiome composition and increased intestinal permeability.

Psychological stress: Chronic psychological stress activates the HPA axis and the sympathetic nervous system, both of which directly affect gut function. Stress increases intestinal permeability through both CRH-mediated and mast cell-mediated mechanisms. Stress also alters gut microbiome composition, reducing populations of beneficial bacteria including Lactobacillus and Bifidobacterium species.

Environmental toxins: Exposure to glyphosate (the active ingredient in the widely used herbicide Roundup), heavy metals, pesticides, and other environmental chemicals can disrupt the gut microbiome and impair tight junction integrity. Glyphosate, in particular, has been shown to potently disrupt the gut microbiome by selectively inhibiting beneficial bacterial species while sparing more pathogenic ones, and growing evidence suggests it directly inhibits TTG and other digestive enzymes (Samsel & Seneff, 2013).

Infections: Gastrointestinal infections, whether viral, bacterial, or parasitic, can acutely disrupt the gut barrier that, in some individuals, does not fully resolve, leaving residual increased permeability and altered microbiome composition. Several studies have documented an increased incidence of celiac disease following certain viral infections, suggesting that post-infectious gut damage can trigger the autoimmune cascade in genetically susceptible individuals.

Age-related changes: The gut microbiome and intestinal barrier function naturally change with age, with progressive reductions in microbiome diversity, alterations in tight junction protein expression, and reduced regenerative capacity of the intestinal epithelium.

When the Bucket Overflows

For decades, the individual’s gut has been absorbing all of these insults. The microbiome has been weakened, the tight junctions have become less stable, and the immune system has been primed by years of low-level activation. The bucket has been filling up.

Then, at some point, the cumulative load of these insults exceeds the gut’s capacity for self-repair and compensation. The bucket overflows. The intestinal barrier becomes sufficiently compromised that gliadin can now cross the epithelial barrier in quantities sufficient to trigger an adaptive immune response in a genetically susceptible individual. The TTG-gliadin complexes are presented to naive CD4+ T cells in the lamina propria. The adaptive immune response is initiated.

This is not an event that happens overnight; it is the culmination of decades of incremental degradation. But the clinical manifestation, the onset of symptoms, can appear quite suddenly once the threshold is crossed, giving the patient the impression that the disease appeared out of nowhere, when in fact it has been building for a very long time.

The Threshold Concept in NCGS

The same threshold concept applies to NCGS, though the mechanism differs somewhat. In NCGS, there is no adaptive immune sensitization to gliadin, no anti-TTG antibody production, and no permanent immunological memory. Instead, the innate immune system’s response to wheat components has become clinically apparent because the cumulative degradation of the gut microbiome and the intestinal barrier has removed the protective buffering that previously kept the innate immune response below the threshold of symptomatic expression.

This distinction matters because it means NCGS is, in principle, reversible: if you can restore the gut microbiome, rebuild the intestinal barrier, reduce the overall inflammatory load, and thereby restore the gut’s buffering capacity, the innate immune response to wheat components may once again be subclinical and non-symptomatic. This is why I say that most of the time, NCGS is manageable and reversible, whereas celiac disease is permanent.

Clinical Application of the Threshold Model

Understanding threshold dynamics has several important clinical implications:

• It explains late onset: Patients who present with new-onset gluten symptoms in their 40s or later are not “developing a new allergy”; their bucket has overflowed, and the predisposition that was always there has now crossed the threshold for clinical expression.
• It points to intervention targets beyond diet: Diet is essential, but reducing the other inputs filling the bucket, including medications, stress, environmental toxins, and dietary triggers of dysbiosis, is equally important for achieving and maintaining recovery.
• It supports a systems-based approach to treatment: Because multiple factors contribute to filling the bucket, a comprehensive, multidisciplinary approach that addresses the gut microbiome, diet, stress, medications, environmental exposures, and structural health simultaneously is more effective than addressing any single factor in isolation.
• It provides a compelling, intuitive explanation that improves patient compliance: In my clinical experience, patients who understand the bucket model are far more likely to make the broad lifestyle changes necessary for gut healing, rather than simply eliminating gluten and expecting a cure.

The TTG-IgA Test: What It Measures, When to Use It, and Why Timing Matters

The Biochemical Basis of the TTG-IgA Test

The anti-tissue transglutaminase IgA (TTG-IgA) test measures the concentration of IgA-class antibodies directed against tissue transglutaminase (specifically TG2) in the patient’s serum. As I explained in the earlier section on the immunological mechanism of celiac disease, B cells in the intestinal lamina propria produce these antibodies after activation by the adaptive immune response to TTG-gliadin complexes.

Most commercial laboratories perform the test using an enzyme-linked immunosorbent assay (ELISA). A blood sample is obtained, the serum is isolated, and the serum is incubated on a plate coated with purified tissue transglutaminase. If anti-TTG IgA antibodies are present in the patient’s serum, they will bind to the TTG on the plate. The bound antibodies are then detected using a labeled secondary antibody that produces a color change proportional to the amount of bound antibody. The result is expressed as a quantitative value with a reference range, and values above the upper limit of normal are considered positive.

Interpreting the TTG-IgA Result

A positive TTG-IgA result in a patient on a regular gluten-containing diet is a strong indicator of celiac disease. Current guidelines recommend that patients with a TTG-IgA level greater than 10 times the upper limit of normal in the presence of compatible symptoms may be diagnosed with celiac disease without the need for intestinal biopsy in some settings. However, biopsy confirmation remains the gold standard in most clinical contexts (Rubio-Tapia et al., 2023).

A negative TTG-IgA result does not definitively rule out celiac disease and must be interpreted in context:

• If the patient is on a regular gluten-containing diet, a negative TTG-IgA is reassuring but does not completely exclude early or seronegative celiac disease
• If the patient has been gluten-free for any period before testing, the result may be falsely negative because antibody titers decline.
• If the patient has selective IgA deficiency, the test may be falsely negative because the patient cannot produce IgA antibodies; in this case, use TTG-IgG or anti-deamidated gliadin peptide IgG (DGP-IgG) testing instead.

The Complete Celiac Serological Panel

While TTG-IgA is the recommended first-line test, a complete celiac antibody panel typically includes:

• TTG-IgA: Primary screening test; highest sensitivity and specificity
• Total serum IgA: Required to rule out selective IgA deficiency, which would make the TTG-IgA test unreliable
• Anti-endomysial antibody IgA (EMA-IgA): Highly specific for celiac disease; useful for confirming equivocal TTG-IgA results; has slightly lower sensitivity than TTG-IgA but very high specificity
• Anti-deamidated gliadin peptide IgG (DGP-IgG): Particularly useful in IgA-deficient patients and in children under 2 years of age, in whom TTG-IgA is less reliable

The Indispensable Importance of the Gluten Challenge

I want to take a moment to emphasize a point that I consider one of the most clinically important and most underappreciated in celiac disease diagnosis: the requirement for an active gluten challenge before serological testing.

The reason this matters so profoundly is that the growing cultural awareness of gluten sensitivity has led a large proportion of patients to self-diagnose and go gluten-free before ever seeking formal medical evaluation. When they eventually do seek a formal diagnosis, often because they want a definitive answer or because a family member has been newly diagnosed, they come for testing having been gluten-free for months or even years.

In this situation, testing the TTG-IgA without first conducting a gluten challenge will almost certainly produce a false-negative result. Anti-TTG IgA antibodies decline toward normal levels within weeks to months after stopping gluten consumption. A patient who has been strictly gluten-free for 6 months before testing will almost certainly test negative, regardless of whether they have celiac disease, because the immunological stimulus for antibody production has been absent for an extended period.

The current standard recommendation is:

• 4 to 6 weeks of regular gluten consumption (at least 10 grams of gluten per day, equivalent to approximately 4 to 6 slices of regular wheat bread) before serological testing
• For patients who have been strictly gluten-free for more than 6 months, some guidelines recommend a challenge period of up to 3 months before testing or proceeding directly to HLA-DQ2/DQ8 genetic testing as a first step; if both HLA-DQ2 and DQ8 are absent, celiac disease can be excluded with high confidence without the need for a gluten challenge.

The decision to undergo a gluten challenge is not always straightforward, as it requires a period of deliberate gluten consumption that may be quite uncomfortable for a patient who is currently feeling well on a gluten-free diet. This is a conversation that I have carefully with patients, weighing the value of a definitive diagnosis against the discomfort and potential health consequences of the challenge period.

Why Going Gluten-Free Before Testing Ruins Your Results

The Biology of Antibody Decline

I want to take a deeper look at the biology behind why going gluten-free before testing creates this problem, because understanding the mechanism helps patients see that this is not simply a matter of clinical caution but a fundamental limitation of the test.

The anti-TTG IgA antibodies measured by the TTG-IgA test are produced by long-lived plasma cells that reside in the bone marrow and secondary lymphoid organs. These cells were originally activated in the intestinal lamina propria in response to the ongoing immune stimulus of TTG-gliadin complexes, then migrated to the bone marrow, where they can survive for years or even decades and continuously secrete antibodies.

However, plasma cell populations are not static; ongoing immune stimulation maintains them. When the antigenic stimulus is removed, the population of plasma cells secreting anti-TTG IgA gradually declines, and serum antibody levels fall accordingly. The rate of decline depends on the antibody’s half-life (approximately 21 days for IgA), the longevity of the plasma cells producing it, and the degree of ongoing immune stimulation.

In practical terms:

• Anti-TTG IgA levels typically begin to fall within 3 to 6 months of strict gluten elimination
• Levels may normalize completely within 6 to 12 months in many patients, though individual variation is significant
• Some patients with very high pre-treatment titers may maintain detectable (though declining) levels for longer periods

This means that a patient who went gluten-free 6 months ago may now have a TTG-IgA level that is either normal or only slightly elevated, even if they had a strongly positive level before going gluten-free. If the clinician interprets this result in isolation, without knowing the patient’s prior dietary history, they may conclude the patient does not have celiac disease, when the negative result reflects the effect of the gluten-free diet rather than the absence of the disease.

The Clinical Consequence: The Diagnostic Dead End

The practical consequence of this problem is what I call the diagnostic dead end: a patient who has self-treated with a gluten-free diet before seeking formal diagnosis finds themselves in a situation where:

1. They feel better on the gluten-free diet, which strongly suggests that gluten is indeed the problem
2. But their serological tests are negative because they have been gluten-free
3. Their doctor, seeing the negative tests, tells them they do not have celiac disease
4. The patient is left without a formal diagnosis, which has significant implications for:

• • Insurance coverage of celiac-related testing and care
  • The seriousness with which their dietary restriction is taken in social and family contexts
  • Their motivation to maintain strict dietary adherence long-term
  • Assessment of their first-degree relatives, who are at increased risk of celiac disease if the proband (index case) has it
  • Guidance about the need for ongoing monitoring for celiac-related complications

At Injury Medical Clinic PA, when we encounter this situation, our approach is to:

1. Conduct HLA-DQ2/DQ8 genetic testing as a first step. If the patient is negative for both HLA-DQ2 and HLA-DQ8, celiac disease is essentially ruled out without the need for a gluten challenge.
2. If the patient carries HLA-DQ2 or HLA-DQ8, discuss a supervised gluten challenge, with appropriate informed consent about potential discomfort and expected duration.
3. If the patient declines the gluten challenge, proceed with the best available evidence from the clinical history, dietary response, and any previous testing to guide management.

Cross-Reactivity and Molecular Mimicry With Dairy: The Science Behind Cutting Out Both

Why Dairy Matters in Celiac Disease Management

When I tell patients with celiac disease that they need to eliminate not just gluten but also dairy, the reaction is almost always one of surprise or resistance. Gluten is now well recognized as the dietary nemesis in celiac disease, but dairy? The connection is less intuitive, yet the scientific basis is well established and clinically significant.

The two mechanisms that explain the dairy-celiac connection are cross-reactivity and molecular mimicry, both of which I introduced briefly earlier and want to elaborate on fully here.

Cross-Reactivity: When the Immune System Sees Similar Faces

Cross-reactivity occurs when an antibody or T cell receptor generated against one specific antigen also binds a different antigen with a sufficiently similar molecular structure. Think of it as a case of molecular mistaken identity: the immune system’s recognition machinery is shape-based, and if two molecules have similar enough three-dimensional shapes in the region recognized by the antibody or T cell receptor, both molecules will be recognized.

In celiac disease, the relevant cross-reactivity is between gliadin peptides and casein peptides. Casein is the primary protein in cow’s milk (constituting approximately 80% of milk protein) and is broken down into several types, including alpha-casein, beta-casein, and kappa-casein. Certain peptide sequences in alpha-gliadin share structural similarity with peptide sequences in alpha-casein, specifically in regions of the protein that are recognized by the immune system’s T cells and antibodies.

The most clinically relevant cross-reactive peptide is alpha-gliadin 33-mer (a 33-amino-acid peptide derived from alpha-gliadin that is the primary immunodominant peptide in celiac disease) and its structural counterparts in bovine casein. Research by Vojdani and Tarash (2013) demonstrated that antibodies raised against various gliadin peptides show immunoreactivity against multiple milk proteins, and conversely, that antibodies raised against casein show immunoreactivity against gliadin peptides.

This means that in a patient with celiac disease whose immune system has produced anti-gliadin and anti-TTG antibodies, those antibodies may also recognize and bind to casein peptides, potentially triggering immune activation in the intestinal mucosa even in the complete absence of gluten. The result is that a patient who is strictly gluten-free but continues to consume dairy may experience persistent intestinal inflammation, ongoing villous damage, and continued symptoms, not because of gluten contamination but because of casein-triggered immune activation through cross-reactivity.

Molecular Mimicry: Antibodies That Attack Self

The second mechanism, molecular mimicry, operates at the level of autoimmunity. In celiac disease, the immune system produces antibodies and activates T cells that recognize the TTG component of TTG-gliadin complexes. But TTG is found throughout the body, so anti-TTG antibodies attack multiple tissues where TTG is expressed.

Now consider that casein, when cross-linked by TTG (which can happen in the intestine), forms casein-TTG complexes that are structurally analogous to gliadin-TTG complexes. These casein-TTG complexes could serve as antigens that drive the same anti-TTG antibody response as gliadin-TTG complexes, effectively amplifying the autoimmune process even in the absence of gluten.

Furthermore, casein-derived peptides, particularly BCM-7 (beta-casomorphin-7), a peptide derived from A1 beta-casein with opioid-like activity, have been shown to directly affect gut permeability and immune function, including stimulating mast cell degranulation and modulating gut motility. These effects can compound the gut barrier dysfunction already present in celiac disease.

The Clinical Case for Eliminating Dairy in Celiac Disease

Based on the evidence I have just described, I recommend to all my patients with confirmed celiac disease that they eliminate cow’s milk dairy products, at least for the initial gut healing period of a minimum of 3 to 6 months, and ideally for 6 to 12 months. The rationale is:

1. Cross-reactivity between gliadin and casein antibodies means that dairy consumption can trigger immune activation even without gluten exposure
2. Secondary lactase deficiency is extremely common in active celiac disease because lactase, the enzyme that digests lactose (milk sugar), is expressed on the brush border of the intestinal villi; when villi are atrophied, lactase production is markedly reduced, making dairy consumption a direct cause of symptoms even apart from the immunological mechanisms.
3. Molecular mimicry between dairy and gluten-related antigens may perpetuate the autoimmune process.
4. A1 beta-casein (found in milk from most commercial dairy breeds) has direct pro-inflammatory effects in the gut that are independent of lactose intolerance.

After the initial gut healing period, if villous architecture has been restored (which can be confirmed by repeat biopsy and normalization of TTG-IgA) and lactase production has recovered, some patients with celiac disease can gradually reintroduce A2 dairy products (dairy from breeds that produce only A2 beta-casein, including goat, sheep, and certain heritage cattle breeds) or fermented dairy products (in which the casein is partially broken down, and the lactose is largely consumed by fermentation) without triggering symptoms. However, this is highly individual, and I take a cautious, monitored approach to dairy reintroduction.

Is It Reversible? Understanding the Difference in Prognosis Between Celiac and NCGS

Celiac Disease: Why the Sensitization Is Permanent

The question of reversibility is one of the most important practical questions for patients with gluten-related disorders. The news is different for celiac disease versus NCGS, and understanding why requires revisiting the fundamental immunological distinction between these two conditions.

Celiac disease involves adaptive immune memory, which is permanent. The B cells and T cells that have been trained to recognize TTG-gliadin complexes and the body’s own TTG are long-lived memory cells that persist in the bone marrow and secondary lymphoid organs for decades. Even after years of complete gluten elimination, these memory cells remain and are ready to mount a rapid, potent immune response upon re-exposure to gluten. This is why celiac disease patients who have been symptom-free for many years on a gluten-free diet can experience a rapid recurrence of symptoms and antibody elevation within days to weeks of reintroducing gluten.

In the strictest biological sense, celiac disease is not reversible at the level of immunological sensitization. The immune system will always be sensitized to gluten-related antigens; the sensitization cannot be “erased.” What can be achieved is disease remission through complete elimination of the dietary trigger, with healing of the intestinal villi, normalization of antibody levels, symptom resolution, and reduced risk of long-term complications. But this remission is conditional and dietary-dependent; remove the dietary restriction and the disease will recur.

This is not a hopeless situation, however. Patients with celiac disease who maintain a strict, permanent gluten-free diet can achieve excellent health outcomes. Intestinal villi regenerate over months to years, nutritional status normalizes, bone density improves, cardiovascular risk decreases, and quality of life can be excellent. The condition is manageable; it is simply not curable through any currently available means.

Future directions in celiac disease research include:

• Enzyme therapy with prolyl endopeptidases that can break down the immunogenic gliadin peptides in the gut before they can trigger an immune response
• TTG inhibitors that prevent the deamidation of gliadin peptides and the formation of TTG-gliadin complexes
• Immune desensitization protocols analogous to allergen immunotherapy
• Tight junction modulators including larazotide acetate, a zonulin antagonist that prevents gluten-induced tight junction opening and has shown promise in clinical trials

NCGS: The Brighter Prognosis

Non-celiac gluten sensitivity, by contrast, is potentially reversible for many patients. Since NCGS does not involve adaptive immune sensitization or the creation of immunological memory, there is no permanent biological barrier to recovery. The innate immune responses that drive NCGS are non-specific and do not create lasting immunological memory; they respond to ongoing stimuli but do not perpetuate themselves once the stimulus is removed.

More importantly, the factors that allowed NCGS to become clinically apparent- the degraded gut microbiome, the leaky intestinal barrier, and the dysregulated innate immune response- are all potentially modifiable. With a comprehensive, integrative approach that addresses all of these factors, many patients with NCGS can:

• Heal and restore the intestinal barrier
• Rebuild a healthy, diverse gut microbiome
• Reduce the overall inflammatory load in the intestinal environment
• Gradually restore tolerance to wheat and gluten at levels that were previously symptomatic

This does not happen quickly or through any simple intervention. It typically requires a commitment of many months to a year or more of active gut healing work, including strict elimination of gluten and other gut irritants during the healing phase, targeted probiotic and prebiotic support, nutritional repletion, stress management, and possibly treatment of underlying dysbiosis or intestinal permeability with specific supplements or pharmaceutical interventions.

But the potential for genuine, lasting recovery, including the ability to tolerate moderate gluten consumption in the future, is real for many patients with NCGS. This differs meaningfully from the permanent, lifelong restriction required for celiac disease, and it matters enormously for patient quality of life and dietary freedom.

Integrative Chiropractic and Functional Medicine: How the Injury Medical Clinic PA Team Treats These Conditions

The Philosophy Behind Our Integrative Approach

At Injury Medical Clinic PA in El Paso, Texas, our clinical philosophy is grounded in a simple but profound idea: the human body is a complex, interconnected system, and effective care requires engaging with that complexity rather than reducing it to isolated organ systems or single diagnoses. This is the foundation of both integrative medicine and functional medicine, and it is the lens through which Dr. Cardenas and I approach every patient.

When a patient comes to us with a presentation that involves gluten-related disorder, whether confirmed celiac disease, suspected NCGS, or simply an unresolved picture of gut symptoms, fatigue, skin issues, and neurological complaints, we do not simply refer them to a gastroenterologist and recommend a gluten-free diet. We conduct a comprehensive evaluation that includes:

• A detailed clinical history exploring the full spectrum of symptoms, their timeline, and their relationship to dietary and lifestyle factors
• A thorough review of previous laboratory work and imaging
• A functional medicine assessment of gut health, nutritional status, hormonal function, inflammatory burden, and microbiome health
• Structural and neurological assessment from a chiropractic and musculoskeletal medicine perspective
• Cardenas’s internal medicine evaluation addressing the systemic manifestations and medical management of the condition

The result is a 360-degree picture of the patient’s health that allows us to design a genuinely comprehensive treatment plan rather than a series of disconnected single-problem interventions.

The Role of Dr. Maria Guadalupe Cardenas: Medical Direction and Internal Medicine Expertise

Dr. Maria Guadalupe Cardenas, MD, brings clinical expertise to our team that is indispensable. With over 40 years of experience as a Board-Certified Internist, Dr. Cardenas brings deep clinical pattern recognition and systems-level medical thinking honed through decades of direct patient care.

Her role in the context of gluten-related disorders includes:

• Medical diagnosis and oversight: Dr. Cardenas reviews and co-signs the medical evaluation for patients presenting with complex gluten-related presentations, ensuring that the full differential diagnosis is considered and that appropriate conventional medical investigation is completed
• Ordering and interpreting laboratory studies: Including the standard celiac serological panel (TTG-IgA, total IgA, EMA-IgA, DGP-IgG), HLA-DQ2/DQ8 genetic testing, and the full panel of nutritional and inflammatory markers that we use in functional medicine evaluation
• Management of systemic complications: Celiac disease patients with significant osteoporosis, anemia, cardiovascular complications, or neurological involvement require medical management that falls squarely within the domain of internal medicine. Dr. Cardenas oversees this aspect of care, including coordinating specialist referrals when needed.
• Medication management: For patients whose presentations require pharmacological intervention, whether for bone protection, anemia management, cardiovascular risk reduction, or other indications, Dr. Cardenas provides the physician-level prescribing oversight
• Collaborative case review: Dr. Cardenas and I review complex cases together regularly, combining our different clinical perspectives to ensure that no dimension of a patient’s presentation is being overlooked

The Role of Chiropractic Care: Structural Health, Nervous System Function, and Systemic Integration

My role as a Doctor of Chiropractic in the management of gluten-related disorders goes beyond simply addressing the structural or musculoskeletal complaints that patients may have alongside their gut symptoms. When practiced within an integrative functional medicine framework, chiropractic care contributes to managing gluten-related disorders through multiple evidence-supported mechanisms.

Spinal assessment and correction: Many patients with untreated or undertreated celiac disease develop musculoskeletal complications that are direct consequences of their nutritional deficiencies. Calcium and vitamin D malabsorption reduces bone density, increasing the risk of vertebral compression fractures and other fragility fractures. Magnesium deficiency contributes to muscle spasm and postural tension. B12 and folate deficiencies affect nerve function, contributing to numbness, tingling, and proprioceptive deficits that can present as balance problems and altered movement patterns.

Chiropractic assessment of the spine in these patients should be informed by awareness of the potential for reduced bone density, and treatment approaches should be appropriately modified to account for that risk. Our assessments routinely include evaluation of bone health risk factors and, when indicated, ordering DEXA (dual-energy X-ray absorptiometry) scans to measure bone density.

Autonomic nervous system regulation: As I mentioned in the section on cytokine overload, the cholinergic anti-inflammatory pathway, mediated primarily by the vagus nerve, is a critical modulator of systemic inflammation. The vagus nerve exits the brainstem and travels through the neck before descending into the thoracic and abdominal cavities, where it innervates the heart, lungs, liver, stomach, intestines, and other visceral organs.

Chiropractic adjustments of the cervical spine, particularly the upper cervical region where the vagus nerve’s accessory fibers exit, have been shown to modulate vagal tone and may enhance the cholinergic anti-inflammatory response (Budgell & Polus, 2006). This is directly relevant to the systemic inflammatory burden of celiac disease and NCGS, as enhanced vagal tone reduces pro-inflammatory cytokine production, including TNF-alpha and IL-6, through the cholinergic anti-inflammatory pathway.

Gut-brain axis support: The gut and brain communicate bidirectionally through the enteric nervous system (ENS), the vagus nerve, the HPA axis, and a growing list of neuroendocrine and immune mediators. This bidirectional communication, collectively called the gut-brain axis, means interventions that improve nervous system function can positively affect gut health, and vice versa.

Chiropractic care that addresses spinal mechanics, reduces pain signaling, and modulates autonomic function contributes to the health of the gut-brain axis. Reducing the chronic sympathetic over-activation associated with chronic pain and spinal dysfunction may improve gut motility, reduce gut permeability, and support the parasympathetic tone that promotes mucosal healing.

Rehabilitation and functional restoration: Many patients with long-standing celiac disease have accumulated significant musculoskeletal dysfunction due to a combination of nutritional deficiencies, chronic fatigue, deconditioning, and the direct effects of chronic systemic inflammation on connective tissue. Corrective exercise, rehabilitation, and movement retraining are essential to restoring functional capacity in these patients, and these services are integral to what we provide at Injury Medical Clinic PA.

The Functional Medicine Framework: Going Beyond Diagnosis to Root Cause Resolution

Functional medicine is the clinical discipline that most explicitly operates at the intersection of conventional medicine and the emerging science of systems biology. Rather than asking “what disease does this patient have?” and then matching a treatment to the diagnosis, functional medicine asks “what are the upstream root causes and dysfunctional processes that are driving this patient’s clinical presentation, and how can we address them at the most fundamental level?”

In the context of gluten-related disorders, this means going beyond the diagnosis of celiac disease or NCGS and systematically evaluating and addressing:

The gut microbiome: Using comprehensive stool analysis panels that measure the composition and function of the gut microbiome, including the presence of beneficial bacteria, opportunistic pathogens, commensal organisms, parasites, and fungi. Targeted probiotic protocols, prebiotic nutrition strategies, and, where appropriate, antimicrobial interventions address specific microbiome imbalances.

Intestinal permeability: Assessed through serum testing of biomarkers including zonulin, intestinal fatty acid binding protein (I-FABP), lipopolysaccharide-binding protein (LBP), and anti-LPS antibodies. The lactulose-mannitol ratio test, a functional test of small intestinal permeability, may also be used in some cases. Elevated intestinal permeability markers guide specific gut-healing interventions.

Nutritional status: Assessed through a comprehensive nutritional panel including serum and red blood cell levels of vitamins (B12, folate, D, A, E, K), minerals (iron, zinc, magnesium, copper, selenium), essential fatty acids, amino acids, and organic acids (as markers of functional deficiencies at the cellular level). The results guide a targeted supplementation protocol.

Inflammatory status: Measured through a panel including high-sensitivity CRP (hsCRP), erythrocyte sedimentation rate (ESR), homocysteine, ferritin, fibrinogen, and a comprehensive cytokine panel in some cases. These markers help quantify systemic inflammation and track response to treatment.

Hormonal and adrenal function: Assessed through testing of cortisol (ideally via a four-point salivary cortisol profile to capture the diurnal rhythm), DHEA-S, thyroid function (including TSH, free T3, free T4, and thyroid antibodies, since celiac disease is associated with increased risk of autoimmune thyroid disease), and sex hormones.

Food reactivity: Beyond specific testing for celiac disease, we may use IgG food sensitivity panels and lymphocyte reactivity testing (LRA testing) to identify other foods driving immune activation in individual patients, since many patients with gut permeability issues have developed reactivity to multiple foods beyond gluten.

Building a Gut Healing Protocol: The Core Elements

Based on the functional medicine evaluation, we design an individualized gut healing protocol for each patient. While every protocol is tailored to the individual, the following are the core elements that we address in most patients with gluten-related gut disorders:

Dietary modification: The cornerstone of any gut healing protocol. For celiac disease patients, this means strict, permanent gluten and dairy elimination. For NCGS patients, this means at minimum a temporary strict elimination of gluten, dairy, and other identified triggers, with a structured reintroduction protocol after the healing phase. We may also implement a low-FODMAP phase for patients with significant digestive symptoms to reduce the gut’s fermentative load while healing occurs.

Digestive enzyme support: Many patients with gut barrier damage have impaired production of digestive enzymes, including pancreatic enzymes and brush border enzymes. Broad-spectrum digestive enzyme supplementation reduces the burden of incompletely digested food antigens reaching the gut immune system and improves nutrient absorption during healing.

Probiotics and prebiotics: We use evidence-based probiotic formulations to support the restoration of a healthy, diverse gut microbiome. Specific strains that have evidence for supporting gut barrier function and reducing intestinal inflammation include Lactobacillus rhamnosus GG, Lactobacillus plantarum, Bifidobacterium longum, and Bifidobacterium infantis. Prebiotic fibers, including inulin, fructooligosaccharides (FOS), and guar gum, feed beneficial bacteria and support the production of short-chain fatty acids (SCFAs), including butyrate, the primary energy source for colonocytes and a key driver of intestinal barrier integrity.

Gut barrier repair nutrients: Specific nutrients have well-established roles in supporting intestinal barrier integrity:

• L-glutamine: The primary fuel for enterocytes; supplementation supports enterocyte energy production and tight junction integrity
• Zinc carnosine: A chelate of zinc and L-carnosine with specific evidence for supporting gastric and intestinal mucosal integrity
• Colostrum: Rich in growth factors including epidermal growth factor (EGF) and insulin-like growth factor 1 (IGF-1) that support intestinal epithelial cell regeneration and tight junction function
• Butyrate supplementation: Direct supplementation with butyrate (typically as sodium or calcium butyrate) supports colonocyte energy production and tight junction expression when dietary sources are insufficient
• Aloe vera gel extract: Has been shown to support mucosal healing and reduce intestinal inflammation
• Deglycyrrhizinated licorice (DGL): Supports mucous membrane integrity throughout the gastrointestinal tract

Anti-inflammatory support: Reducing the gut’s inflammatory burden promotes mucosal healing. Key anti-inflammatory interventions include:

• Omega-3 fatty acids (EPA/DHA): Potent anti-inflammatory effects through reduction of arachidonic acid-derived pro-inflammatory eicosanoids and promotion of pro-resolving lipid mediators
• Curcumin (turmeric extract): Inhibits NF-kB, the master transcription factor of inflammation, and downregulates TNF-alpha, IL-6, and IL-1beta production
• Quercetin: A flavonoid with evidence for stabilizing mast cells, reducing intestinal permeability, and downregulating inflammatory cytokine production
• Resveratrol: Activates SIRT1 (sirtuin-1), which has anti-inflammatory and gut-protective effects

Stress management: Given the profound impact of chronic stress on gut permeability and immune function, stress management is not an optional add-on but a core component of gut healing. We work with patients to implement practical stress management strategies including:

• Mindfulness-based stress reduction (MBSR)
• Diaphragmatic breathing exercises, which directly stimulate the vagus nerve and enhance parasympathetic tone
• Yoga and gentle movement therapies, which combine physical activity with breathwork and mindfulness
• Sleep optimization, since sleep deprivation is itself a potent activator of the HPA axis and a driver of gut permeability.

Environmental toxin reduction: Advising patients on reducing their exposure to gut-disrupting environmental chemicals, including choosing organic produce to reduce glyphosate exposure, filtering drinking water, reducing use of personal care products containing gut-disrupting chemicals, and addressing any identified heavy metal exposures.

Clinical Observations From Dr. Alex Jimenez: Patterns Seen in Practice

What I See in the Clinic: Patterns in Gluten-Related Presentations

Over the years, clinical practice documented through my work atSciaticaat Sciaticaand my professional record available on LinkedIn, I have observed several consistent clinical patterns in patients presenting with gluten-related disorders. These observations shape my approach to evaluation and treatment and complement the research literature with the lived reality of clinical practice.

Pattern 1: The misdiagnosed neurological presentation. A significant proportion of patients who present to my clinic with neurological complaints, including peripheral neuropathy, balance problems, and unexplained sensory symptoms, have an underlying gluten-related disorder that has never been considered in their diagnostic workup. In many cases, these patients have seen multiple neurologists and have had extensive conventional neurological workups including nerve conduction studies, MRI, and blood work, all of which were unremarkable or yielded non-specific findings. When we add celiac and gluten antibody testing, along with a thorough gut health assessment, we often find the missing piece.

Pattern 2: The chronic musculoskeletal patient with hidden nutritional deficiencies. Patients presenting with chronic low back pain, joint pain, and fibromyalgia-like presentations often have significant underlying nutritional deficiencies, particularly of vitamin D, magnesium, and zinc, driven by a subclinical gut malabsorption problem. When we investigate the gut in these patients, gluten reactivity is common. Addressing the gut and nutritional deficiencies often produces dramatic improvements in musculoskeletal symptoms that years of conventional treatment failed to resolve adequately.

Pattern 3: The late-onset presentation in the 40s-60s. Consistent with the bucket theory I described earlier, I see a disproportionate number of patients who developed their first clear symptoms of gluten-related disorder in middle age, often following a period of significant stress, a major illness, or an extended course of antibiotics. These patients invariably have a history of gut stress that, looking back, makes the timing of their onset comprehensible.

Pattern 4: The patient who is “mostly gluten-free” but not improving. A common presentation involves patients who have already eliminated most obvious gluten sources but continue to have symptoms. The issue is almost always one of the following: hidden gluten sources in processed foods, sauces, and medications; dairy cross-reactivity driving continued immune activation; or incomplete gut healing due to insufficient attention to the broader gut restoration protocol. Identifying which of these factors is driving the residual symptoms is a key part of our assessment.

Pattern 5: The skin patient referred in circles. Patients with dermatitis herpetiformis frequently have a history of being treated for eczema, psoriasis, or contact dermatitis for years without a correct diagnosis. The telling feature is the distribution and character of the lesions, combined with intense pruritus and typical extensor-surface involvement. When we test these patients, we almost always find elevated anti-TTG IgA levels and, in many cases, the diagnosis of celiac disease has been present for years without recognition.

The El Paso Population: Unique Considerations

Our patient population in El Paso, Texas reflects the demographics of a predominantly Hispanic and Latino community with significant historical and cultural ties to traditional dietary practices. Traditional Mexican and Tex-Mex cuisine is largely based on corn (maize), beans, and rice rather than wheat, so in many traditional households, gluten exposure is historically lower than in diets based predominantly on wheat bread and pasta.

However, the progressive Americanization of dietary patterns, with increased consumption of fast food, highly processed wheat-based foods, and ultra-processed snacks, has dramatically increased gluten exposure in the El Paso population over the past two to three decades. At the same time, the health consequences of this dietary transition, including increasing rates of obesity, type 2 diabetes, and inflammatory conditions, have created a patient population with a significant chronic disease burden that creates exactly the conditions for the bucket to fill and overflow.

The genetics of the Hispanic and Latino population present a somewhat different picture from European populations with respect to celiac disease. The prevalence of HLA-DQ2 and HLA-DQ8 varies across populations. Several studies have suggested that the prevalence of celiac disease in Latin American populations may be comparable to European rates. However, it is substantially underdiagnosed due to a lower clinical index of suspicion and limited access to appropriate serological testing in some healthcare settings (Gomez et al., 2001).

Our practice strongly emphasizes cultural competence in clinical communication. When discussing dietary modifications with patients in El Paso, we are always mindful of the cultural significance of food, the practical challenges of dietary change in a family and community context, and the importance of finding culturally appropriate substitutions and alternatives that make the dietary transition sustainable long-term.

Building a Treatment Protocol: What a Comprehensive Integrative Approach Looks Like

The Five-Phase Protocol for Gluten-Related Gut Healing

Drawing on the functional medicine framework, the research literature, and our team’s clinical experience at Injury Medical Clinic PA, we developed a five-phase integrative treatment protocol for patients with gluten-related disorders. This protocol is individualized for each patient based on their specific diagnosis, functional medicine assessment findings, and personal circumstances, but the following describes the general framework.

Phase 1: Accurate Diagnosis and Baseline Assessment

Duration: Approximately 4 to 6 weeks, including the gluten challenge period if relevant

Goals: Establish an accurate diagnosis, characterize the severity and extent of the condition, and identify all relevant contributing factors and comorbidities

Key activities:

• Complete celiac serological panel (TTG-IgA, total IgA, EMA-IgA, DGP-IgG) with appropriate gluten challenge preparation
• HLA-DQ2/DQ8 genetic testing if indicated
• Comprehensive functional medicine laboratory panel (nutritional status, inflammatory markers, adrenal function, thyroid function, gut permeability markers, microbiome analysis)
• Musculoskeletal and neurological assessment
• DEXA scan for bone density if clinically indicated
• Cardenas’s internal medicine evaluation
• Dietary history and food diary review
• Patient education on the distinction between celiac disease and NCGS, the mechanisms of gluten-related harm, and the rationale for the treatment protocol

Phase 2: Remove and Reduce

Duration: 8 to 12 weeks

Goals: Eliminate the dietary and environmental triggers that are driving the immune response and gut inflammation; begin initial repair of the intestinal barrier

Key activities:

• Implementation of a strict gluten-free diet (and dairy-free for celiac disease patients and NCGS patients with evidence of dairy reactivity)
• Implementation of a low-FODMAP protocol if significant fermentative symptoms are present
• Identification and elimination of hidden gluten sources in processed foods, medications, and personal care products
• Reduction of gut-disrupting medications where clinically appropriate and safe (with Dr. Cardenas’s medical oversight)
• Reduction of environmental glyphosate and pesticide exposure through dietary modification (choosing organic)
• Stress reduction protocol implementation
• Initiation of basic gut repair supplements: L-glutamine, zinc carnosine, digestive enzymes, omega-3 fatty acids

Phase 3: Replace and Restore

Duration: 12 to 24 weeks (overlapping with Phase 2)

Goals: Restore the nutritional deficiencies identified in Phase 1; support the regeneration of intestinal villi; rebuild the gut microbiome

Key activities:

• Targeted nutritional supplementation based on laboratory findings: iron (if deficient), calcium and vitamin D3/K2 (for bone health support), B12 and folate (if deficient), magnesium, zinc, and other identified deficiencies
• Probiotic and prebiotic protocol: Multi-strain, high-potency probiotic formulation with prebiotic fiber support
• Gut barrier repair protocol: L-glutamine, colostrum, aloe vera, DGL, zinc carnosine, butyrate (if indicated)
• Enzyme therapy: Digestive enzyme supplementation to support nutrient absorption during the healing phase
• Anti-inflammatory supplementation: Curcumin, quercetin, resveratrol, omega-3 fatty acids
• Chiropractic care beginning or continuing: Spinal assessment and adjustment, soft tissue therapy, and rehabilitation exercise to address musculoskeletal consequences of nutritional deficiency and chronic inflammation

Phase 4: Repair and Reinoculate

Duration: 3 to 6 months

Goals: Complete the healing of the intestinal mucosa; achieve a healthy, stable gut microbiome; address residual systemic manifestations of the condition

Key activities:

• Repeat laboratory assessment to confirm improving nutritional status, declining inflammatory markers, and falling TTG-IgA levels (in celiac disease)
• Endoscopic re-evaluation if initial biopsy showed significant villous atrophy, to confirm mucosal healing
• Bone density monitoring with repeat DEXA if initial scan showed osteopenia or osteoporosis
• Advanced gut microbiome testing to assess the composition and functional recovery of the microbiome
• Stress resilience building: Advanced mindfulness and resilience training, vagal tone exercises, sleep hygiene optimization.
• Continued chiropractic care with progressive rehabilitation: Increasing emphasis on functional movement, strength building, and proprioceptive rehabilitation as energy levels and musculoskeletal function improve
• Introduction of prebiotic-rich foods: Gradual introduction of a wider variety of fermentable fibers to support microbiome diversity

Phase 5: Reintroduce and Reassess (NCGS patients only)

Duration: 3 to 6 months

Goals: For NCGS patients who have achieved comprehensive gut healing, carefully test tolerance for gradual reintroduction of wheat-containing foods; establish a long-term dietary baseline that is symptom-free and immunologically tolerable

Key activities:

• Structured food reintroduction challenge: Beginning with small amounts of ancient wheat varieties (einkorn, emmer, spelled) that are lower in ATIs and modern gliadin content, and gradually working toward conventional wheat if tolerated
• Monitoring for symptom recurrence and, in some cases, repeat functional laboratory testing to ensure that reintroduction is not driving occult immune activation.
• Personalized long-term dietary recommendations: Based on the outcomes of the reintroduction phase, developing a long-term eating pattern that is individualized to the patient’s level of gluten tolerance and optimized for gut microbiome diversity and systemic health
• Ongoing maintenance support: Establishing a maintenance supplementation protocol and periodic monitoring schedule to ensure continued health

Note: This Phase 5 applies exclusively to patients with confirmed NCGS, never to patients with celiac disease. For celiac disease patients, the dietary restriction is permanent and non-negotiable, and there is no structured reintroduction phase.

Personal Injury and Rehabilitation Considerations

At Injury Medical Clinic PA, a significant portion of our clinical work involves patients presenting with personal injury cases, including motor vehicle accident victims, workplace injury claimants, and slip-and-fall cases. The intersection of personal injury care and gluten-related disorders is more common than might initially seem apparent.

Patients who have been in accidents and who are recovering from soft tissue injuries, spinal injuries, or traumatic brain injuries often have a pre-existing inflammatory burden, sometimes driven by unrecognized gluten-related disorders, that significantly impairs their healing capacity. Chronic systemic inflammation, whether from celiac disease, NCGS, or another inflammatory condition, delays tissue repair, impairs collagen synthesis, reduces pain tolerance, and extends recovery timelines.

When we identify evidence of a gluten-related disorder in a personal injury patient, addressing that underlying condition becomes an integral part of the injury rehabilitation plan. Reducing the baseline inflammatory burden, addressing nutritional deficiencies that impair tissue repair, and restoring gut health can dramatically improve the trajectory of injury recovery.

Dr. Cardenas’s medical direction is particularly important in these cases, ensuring that the personal injury documentation reflects the multidimensional nature of the patient’s condition and that the medical evidence supporting the treatment approach is well documented and defensible.

Conclusion: The Gluten Conversation Deserves More Than a One-Size-Fits-All Answer

The story of gluten, the immune system, and the gut is one of the most complex and consequential stories in modern medicine. What began as an understanding of a rare childhood malabsorption syndrome has expanded, through decades of dedicated research, into a recognition of a spectrum of gluten-related disorders with mechanisms that span the adaptive and innate immune systems, symptoms that extend from the gut to the brain to the skin to the bones and cardiovascular system, and consequences that, in the case of untreated celiac disease, are severe, systemic, and irreversible.

The single most important clinical message I want you to take from this post is that celiac disease and NCGS are not the same condition; they require different diagnostic approaches, different management strategies, and different expectations about prognosis, and they deserve the careful, individualized attention that a multidisciplinary integrative clinical team is uniquely positioned to provide.

The second most important message is that the gut is the center of gravity of many of the most challenging chronic conditions we face in modern medicine. The intestinal barrier, the microbiome, the gut immune system, and the gut-brain axis are not peripheral players in human health; they are central. When the gut fails, the consequences ripple outward through every organ system. When the gut heals, those ripples reverse direction.

At Injury Medical Clinic PA, with the clinical partnership of Dr. Alex Jimenez, DC, APRN, FNP-BC, and Dr. Maria Guadalupe Cardenas, MD, we are committed to providing the comprehensive, evidence-based, integrative care these conditions demand. If you are in El Paso, Texas, or the surrounding region and you are struggling with a gluten-related condition, a complex gut health presentation, or any of the systemic manifestations described in this post, I encourage you to reach out. You deserve a complete picture, not just a piece of it.

References

• Budgell, B., & Polus, B. (2006). The effects of thoracic manipulation on heart rate variability: A controlled crossover trial. Journal of Manipulative and Physiological Therapeutics, 29(8), 603-610.
• Catassi, C., Bai, J. C., Bonaz, B., Bouma, G., Calabro, A., Carroccio, A., Castillejo, G., Ciacci, C., Cristofori, F., Dolinsek, J., Francavilla, R., Elli, L., Green, P., Holtmeier, W., Koehler, P., Koletzko, S., Meinhold, C., Sanders, D., Schumann, M., Schuppan, D., … Fasano, A. (2013). Non-celiac gluten sensitivity: The new frontier of gluten-related disorders. Nutrients, 5(10), 3839-3853.
• Fasano, A. (2012). Leaky gut and autoimmune diseases. Clinical Reviews in Allergy and Immunology, 42(1), 71-78.
• Fasano, A., Not, T., Wang, W., Uzzau, S., Berti, I., Tommasini, A., & Goldblum, S. E. (2000). Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. The Lancet, 355(9214), 1518-1519.
• Gomez, J. C., Selvaggio, G. S., Viola, M., Pizarro, B., La Motta, G., de Barrio, S., Castelletto, R., Echeverria, R., Sugai, E., Vazquez, H., Maurino, E., & Bai, J. C. (2001). Prevalence of celiac disease in Argentina: Screening of an adult population in the La Plata area. American Journal of Gastroenterology, 96(9), 2700-2704.
• Junker, Y., Zeissig, S., Kim, S. J., Barisani, D., Wieser, H., Leffler, D. A., Zevallos, V., Libermann, T. A., Dillon, S., Freitag, T. L., Kelly, C. P., & Schuppan, D. (2012). Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. Journal of Experimental Medicine, 209(13), 2395-2408.
• Ludvigsson, J. F., Michaelsson, K., Ekbom, A., & Montgomery, S. M. (2012). Coeliac disease and the risk of fractures – a general population-based cohort study. Alimentary Pharmacology and Therapeutics, 25(3), 273-285.
• Rubio-Tapia, A., Hill, I. D., Semrad, C., Kelly, C. P., Greer, K. B., Limketkai, B. N., & Lebwohl, B. (2023). American College of Gastroenterology clinical guideline: Diagnosis and management of celiac disease. American Journal of Gastroenterology, 118(1), 59-76.
• Rubio-Tapia, A., & Murray, J. A. (2007). The liver in celiac disease. Hepatology, 46(5), 1650-1658.
• Samsel, A., & Seneff, S. (2013). Glyphosate, pathways to modern diseases II: Celiac sprue and gluten intolerance. Interdisciplinary Toxicology, 6(4), 159-184.
• Skodje, G. I., Sarna, V. K., Minelle, I. H., Rolfsen, K. L., Muir, J. G., Gibson, P. R., Veierod, M. B., Henriksen, C., & Lundin, K. E. A. (2018). Fructan, rather than gluten, induces symptoms in patients with self-reported non-celiac gluten sensitivity. Gastroenterology, 154(3), 529-539.
• Sollid, L. M., & Lie, B. A. (2005). Celiac disease genetics: Current concepts and practical applications. Clinical and Experimental Immunology, 140(2), 218-224.
• Vojdani, A., & Tarash, I. (2013). Cross-reaction between gliadin and different food and tissue antigens. Food and Nutrition Sciences, 4(1), 20-32.
• Volta, U., Bardella, M. T., Calabro, A., Troncone, R., Corazza, G. R., & the Study Group for Non-Celiac Gluten Sensitivity. (2014). An Italian prospective multicenter survey on patients suspected of having non-celiac gluten sensitivity. BMC Medicine, 12, 85.
• Welch, A., & Boone, R. (2008). Sympathetic and parasympathetic responses to specific diversified adjustments to chiropractic vertebral subluxations of the cervical and thoracic spine. Journal of Chiropractic Medicine, 7(3), 86-93.
• World Gastroenterology Organization. (2016). WGO global guidelines: Celiac disease. World Gastroenterology Organization.

SEO Tags: celiac disease vs gluten sensitivity, non-celiac gluten sensitivity, TTG-IgA test celiac, gluten leaky gut, intestinal villi damage celiac, gliadin zonulin gut barrier, molecular mimicry celiac dairy, dermatitis herpetiformis gluten, celiac disease osteoporosis, gluten neuropathy, adaptive immune response celiac, innate immune response NCGS, bucket theory gut health, gluten challenge testing, dairy cross-reactivity celiac, Dr. Alex Jimenez El Paso, Dr. Maria Guadalupe Cardenas MD, Injury Medical Clinic PA, integrative chiropractic functional medicine, gut brain axis inflammation, celiac disease nutrient malabsorption, villous atrophy celiac, tight junction intestinal permeability, amylase trypsin inhibitors wheat, HLA-DQ2 HLA-DQ8 celiac genetics, gluten free diet celiac disease, chiropractic care systemic inflammation, vagus nerve anti-inflammatory pathway, gut healing protocol functional medicine, El Paso integrative medicine